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Abstract 
 
Progress has been made in using human serum albumin nanoparticles (HSAPs) as carrier 
systems for targeted treatment of cancer. Human serum albumin (HSA), the most abundant 
human blood protein, can form HSAPs via a desolvation and crosslinking method, with the size 
of the HSAPs having crucial importance for drug loading and in vivo performance. Gold 
nanoparticles have also gained medicinal attention due to their ability to absorb near-infrared 
(NIR) light. These relatively non-toxic particles offer combinational therapy via imaging and 
photothermal therapy (PPTT) capabilities.  
A desolvation and crosslinking approach was employed to encapsulate gold nanoparticles 
(AuNPs), hollow gold nanoshells (AuNSs), and gold nanorods (AuNRs), into efficiently sized 
HSAPs for future tumor heat ablation via PPTT. The AuNR-HSAPs, AuNP-HSAPs and AuNS-
HSAPs had average particle diameters of 222 ± 5, 195 ± 9 and 156 ± 15, respectively.  
We simultaneously encapsulated AuNRs and the anticancer drug paclitaxel (PAC), 
forming PAC-AuNR-HSAPs with overall average particle size of 299 ± 6 nm. Loading of 
paclitaxel into PAC-AuNR-HSAPs reached 3μg PAC/mg HSA.  PAC-AuNR-HSAPs 
experienced photothermal heating of 46 ˚C after 15 minutes of NIR laser exposure; the 
temperature necessary to cause severe cellular hyperthermia. There was a burst release of 
paclitaxel up to 188 ng caused by the irradiation session, followed by a temporal drug release.   
AuNR-HSAPs were tested for ablation of renal cell carcinoma using NIR irradiation in 
vitro. Particles created with the same amount of AuNRs, but varying HSA (1, 5 or 20 mg) 
showed overall particle size diameters 409 ± 224, 294 ± 83 and 167 ± 4 nm, respectively.  
Increasing HSAPs causes more toxicity under non-irradiated treatment conditions: AuNR-
 xi
HSAPs with 20 mg versus 5 mg HSA caused cell viability of 64.5% versus 87%, respectively. 
All AuNR-HSAPs batches experienced photothermal heating above 42 ˚C. Coumarin-6, was 
used to visualize the cellular uptake of AuNR-HSAPs via fluorescence microscopy.  
Finally, camptothecin (CPT) an antineoplastic agent and BACPT (7-butyl-10-
aminocamptothecin) were loaded into HSAPs to combat their aqueous insolubility. BACPT-
HSAPs loaded up to 5.25 micrograms BACPT/ mg of HSA. CPT encapsulation could not be 
determined. BACPT-HSAPs and CPT-HSAPs showed cytotoxicity to human sarcoma cells in 
vitro.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Hybrid Nanoparticles, Photothermal Therapy, Gold Nanomaterials, Drug Delivery, 
Combinational Cancer Therapies, Materials, Human Serum Albumin, Colloidal Carriers.
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Chapter 1 
 Introduction 
1.1 Objectives and Aims 
The objective of this research project was to develop hybrid gold nanomaterial and drug-loaded 
human serum albumin nanoparticles (HSAP) for custom chemotherapeutic/photothermally active 
cancer therapy platforms.  HSAPs offer a combination of diagnostic and treatment functionalities 
which are unique to them, when considering their natural biological protein makeup.  They have the 
inherent ability to seek out areas of increased blood flow, such a tumor sites, and accumulate there.  
This accumulation can prove diagnostically helpful when HSAPs are conjugated to a contrast agent. 
Due to the accumulation of the particles at tumor sites, they have the potential for controlled release 
of drugs as well as the capacity for inclusion of other therapy outlets, such as hyperthermia. 
The advantages characteristic of a hybrid treatment system allow for simultaneous targeting, 
detection and multimodal therapy avenues, which do not currently exist in any one clinical therapy 
option. This research work was specifically designed to 1) develop and understand a preparation 
method for encapsulating gold nanomaterials into HSAPs, 2) prove the near-infrared triggered 
heating capabilities of the gold nanomaterials even while they were encapsulated in the protein shell, 
3) simultaneously include proven chemotherapeutic drugs into the gold-HSAPs and determine the 
loading efficiencies and 4) test the heating and drug delivery effects of the drug-gold-HSAPs as 
compared to particle controls in vitro. 
1.2 Significance 
Cancer is an enormous global health problem, accounting for 1 in 8 deaths worldwide.1 
The financial cost of a disease of this magnitude is also staggering, so there is a definite crucial 
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need for more efficient, less invasive, and cheaper treatments that eliminate the severe symptoms 
of the therapies currently available.  Human serum albumin (HSA), the most abundant human 
blood protein, offers natural biocompatibility and biodegradability and is capable of conjugating 
drugs, metallic nanoparticles, and other organic and inorganic substances via covalent and non-
covalent attachment of its many functional groups 2, 3, 4, 5.  This research work focused on 
encapsulating solid gold nanoparticles, hollow gold nanoshells and gold nanorods into human 
serum albumin nanoparticles (HSAPs), as well as four other chemotherapeutics: paclitaxel, 
camptothecin, and 7-butyl-10-aminocamptothecin (BACPT) to show that the combination and 
size optimization of these hybrid particles can serve as platforms for preparing new drug 
therapies.  Despite the clinical success of drug loaded HSAPs, there is a current lack of multi-
functional HSAP hybrids that offer combinational therapies. This particle template allows for 
potential simultaneous inclusion of anti-cancer drugs, biomarkers, or other 
imaging/photodynamic molecules, along with photothermally active gold nanomaterials.  The 
strategy also allows for subsequent external surface functionalizing to improve control of HSAP 
behavior in the body. 
The combined approach will permit killing of cancer cells by both hyperthermal 
treatment and localized chemotherapy treatment.  The combination of treatments is more likely 
to eliminate all cancer cells.  The simplicity in the HSAP synthesis and entrapment of the gold 
materials, and the effectiveness of maintaining the HSA’s stability and ability to bind internal 
and external molecules, provide a better approach in the field of photothermal therapies using 
nanoparticles.  This novel approach will provide significant contributions in the fields of nano-
scale drug delivery and photothermal/photodynamic therapy.  Since our findings could be 
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utilized to further site-specific, targeted anti-cancer therapy approaches, it can potentially boost 
effectiveness and reduce damage to healthy tissue. 
1.3 Human Serum Albumin Nanoparticles 
Human serum albumin (HSA) is a heart-shaped, globular protein made up of 585 amino 
acid residues with only one central, fluorescent tryptophan.3  HSA offers natural biocompatibility 
and biodegradability, as well as the capability to be surface functionalized due to its high content 
of charged amino acids.2, 5, 6,  Molecular HSA has a blood concentration of 7 × 10-4 M and a total 
mass of approximately 120 g, making up 50% of the protein present in plasma.3, 4, 7,  Each HSA 
molecule makes about 15,000 passes through the circulatory system during its 28-36 day 
lifespan; picking up and unloading numerous endogenous and exogenous compounds.  This vital 
protein is able to make its way into the central nervous system and even across the blood-brain 
barrier.3, 4, 7  
HSAPs have been utilized in promising controlled release studies due to enhanced 
permeability and retention effects (EPR), where molecules or particles of certain sizes 
accumulate at tumor sites upon stimulation of the production of blood vessels during rapid, 
irregular growth.8, 9  This effect is especially true for molecules greater than 40 kDa, which are 
more readily trapped. Malignant tumors induce and increase angiogenesis and consequently, 
hypervascularization. Rapid blood vessel growth in tumors causes an irregular structure with 
pore sizes of 200-600 nm, thus allowing particles of ~200 nm to easily be taken into the tumor 
site.9, 10  Once particles enter the tumor, there is not sufficient lymphatic drainage to remove 
them; thus longer retention of carrier systems such as liposomes and albumin particles is 
accomplished. 10, 11, 12, 13  Because of the natural tendency for blood accumulation at tumor sites, 
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a prominent blood protein like HSA is a strong candidate for this type of EPR substantiated 
cancer treatment vehicle.   
The primary protein structure of molecular HSA allows for conjugating drugs, metallic 
nanoparticles and other organic and inorganic substances via covalent attachment of its 
functional groups, such as amine and carboxylic acid groups.2   The creation of HSAPs as a 
colloidal drug carrier system multiplies this ability and allows for transport of toxic or low 
solubility drugs with high loading efficiency (better than liposomes), good storage competence, 
and minor leakage.11,14   
Chemotherapeutic drugs have severe symptoms associated with them including drug 
resistance and myelosuppression, where bone marrow activity is decreased, resulting in fewer 
red blood cells, white blood cells, and platelets; so a contained transport method that delivers 
drug only to the site of disease is desired.15, 16   HSA’s natural biocompatibility makes it capable 
of conjugating drugs and hiding them, thus changing their pharmacokinetic profiles for stealth 
drug delivery.3, 17  HSAPs have already been proven as safe medical transporters by the clinical 
formulations of AlbunexTM, an echocardiographic contrast agent made of sonicated, air-filled 
HSA microspheres and AbraxaneTM, paclitaxel filled HSAPs for the treatment of lung, ovarian, 
breast, head, and neck cancer. 11, 15    
1.3.1 Synthesis of HSAPs 
Desolvation is a simple, thermodynamically driven self-assembly process for polymeric 
materials by the addition of a desolvating, or denaturing, agent which coacervates the 
polypeptide molecules in the aqueous phase, thus facilitating electrostatic and hydrophobic 
interactions.14, 18  Because of this dependence on the attractive and repulsive forces, the pH of the 
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HSA aqueous solution prior to the addition of ethanol plays a pivotal role in the ultimate size of 
the formed particles, and the later influences cancer extracellular matrix interactions.14,19   
Glutaraldehyde is used as a cross-linking reagent to covalently bond two amine groups. 
The glutaraldehyde is needed to strengthen the HSA acervates into place after denaturation and 
aggregation. The HSA amines of the 59 lysine residues and 23 arginine moieties in guanidino 
side chains are crosslinked by a condensation reaction with the aldehyde groups of 
glutaraldehyde.20 It has been calculated that the lowest required amount of glutaraldehyde 
needed to quantitatively crosslink all 59 ε-amino groups present in 100 mg of HSA is 
approximately 4.7 × 10-5 moles of glutaraldehyde (58.8 μL of 8% by volume glutaraldehyde in 
H2O).20 
1.5 Photothermal Therapy and Cell Hyperthermia 
Plasmonic photothermal therapy (PPTT) is the phenomena whereby a metal’s surface 
electrons interact with a frequency of light that matches the resonant frequency of the electrons. 
Oscillations of the surface electrons, called plasmons, move in harmony with the wave resulting 
in absorption.21  Through a photothermal conversion, the absorbed light is transferred to heat 
energy.  The therapeutic capability occurs if the wavelength of the radiation is in the biologically 
safe water window (700-900 nm); with near infrared light being able to penetrate tissue in vivo at 
a tumor site up to 10 cm below the skin, without affecting surrounding healthy cells. 21, 22, 23  This 
particular phenomenon of heating gold nanomaterials has previously been successfully proven 
safe for in vivo applications. 21, 24, 25  
Moderate cell hyperthermia occurs at 43˚C and can cause increases in endocytosis and 
blood flow, resulting in not only an increase in uptake of drugs, but a break down intracellular 
structure 26.  Increasing the induced temperature to over 46˚C will cause severe hyperthermia and 
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eventual cell death through heat ablation. 27  This type of induced heat therapy shows immediate 
anticancer effects, however the full benefits are hindered due to the distribution of energy within 
the beam and the gradual reduction of heat in the tissues farther from the AuNR. 28  Therefore, 
developing a hybrid mechanism which would also carry a proven chemotherapeutic drug along 
with the AuNRs, with relatively long-lasting effects, was in order. 
1.6 Gold Nanoparticles, Nanoshells and Nanorods 
There has also been an emergence of new synthesis routes to manipulate gold into 
nanomaterials of various shapes and sizes for therapeutics and other applications. 29, 30, 31, 32  Gold 
nanorods (AuNRs), nanoparticles (AuNPs), and nanoshells (AuNSs) have the ability to absorb 
and/or elastically scatter light, depending on the gold’s shape and size. The scattering ability 
makes them remarkable contrast imaging agents in vivo and the absorption of photons with 
matching frequencies causes the subsequent release of energy via heat, which can be harnessed 
for use in plasmonic photothermal therapy.33, 34, 35, 36  Nano-sized gold’s unique absorption 
properties are due to surface plasmon resonance, with the resonant frequency varying with the 
shape, size, and environment of the gold particle. 21   
AuNPs are inert with bio-conjugation ability, especially with thiolated molecules, 
fluorophores and blood proteins like HSA. Since these particles are usually small (2-80 nm), they 
are perfect for endocytosis (25-80 nm caveolae mediated uptake and up to 100 nm clatherin 
mediated uptake).  When the particles are encapsulated within a larger matrix, like an HSAP, 
phagocytosis is a more common uptake mechanism.31, 37, 38, 39, 40   
In particular, AuNRs absorption maxima can span a wide range of wavelengths due to the 
fact that the particles have two distinct plasmon bands created by the transverse (short) axis and 
the longitudinal (long) axis.  Longer rods usually yield larger plasmon frequencies.32  Also, 
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unlike spherical gold nanoparticles which are more likely to quench fluorescence via 
fluorescence resonance energy transfer (FRET), AuNRs can enhance quantum yields of 
fluorescent molecules at certain distances.30  This could be very useful for imaging if a 
fluorophore is maximally loaded into the HSAP shell surrounding the gold nanorod. 
PEGylated gold nanorods have shown to be the least toxic type of gold nanoparticle both in 
vitro and in vivo and have ideal photothermally active traits.  However, one study found that they 
have a down side: they are rapidly excreted from the body and usually have a half-life of 
approximately 1 hour. 41  Therefore, for in vivo efficiency, the composite particle size range of 
100-500 nm is still ideal.42  During the rapid development of new, irregular blood vessels, 
normal vascular structures are impeded, thus resulting in openings in the capillaries from 200 to 
2000 nm, which allow larger particles in. 43  From there, lymphatic drainage of interstitial fluids 
in the tumor site is abnormal; causing smaller particles to freely move back into circulation, 
while larger particles are maintained in the tumor. 44 Therefore, it would be beneficial to 
encapsulate rod-shaped gold particles into spherical HSAPs to increase overall size and loading 
capabilities.  The majority of this work focuses on the encapsulation of gold nanorods into 
HSAPs. 
1.7 CPT and BACPT 
Natural products are successful sources of antineoplastic agents, accounting for greater 
than 60% of the anticancer pharmaceuticals in use. 45  Camptothecin (CPT), an alkaloid isolated 
from Camptotheca acuminata (the “happy tree” in China) was first isolated and reported in 
1966.46, 47   Camptothecin is greatly used on primary and metastatic colon carcinoma, platinum-
refractory ovarian cancer, and small cell lung carcinoma. It acts by poisoning the DNA target 
enzyme topoisomerase I (top I) during its catalytic cycle of DNA relaxation, leading to the 
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generation of DNA double-strand breaks and cell death by apoptosis.46,48,49,50  The problem 
associated with camptothecin is that it possesses extremely low aqueous solubility; consequently 
it failed in initial clinical trials conducted in the 1970s.  
To reduce side effects and enhance potency, water soluble analogues of camptothecins, 
namely topotecan (TPT) and irinotecan (CPT-11), were created and are increasingly in clinical 
use for colorectal, ovarian and lung cancers.  Despite their success, major side effects are caused 
by the water-solubilizing functionalities, such as severe to life-threatening diarrhea and 
myelosuppression (where bone marrow activity is decreased, resulting in fewer red blood cells, 
white blood cells, and platelets).,15,16, 51  Because of this, these camptothecin derivatives are dose-
limiting. 52   
Other methods have been explored to keep the camptothecins in their most effective state 
such as: encapsulating them within dendrimers (large, branched molecules), delivering them in 
conjunction with surfactants and linking them to large water-soluble polymers (e.g., 
PEGylation).52,53  In most cases, there are still side effects and reduced anticancer efficacy.  
Hiding the highly effective CPT (or BACPT) in a biocompatible protein shield will accomplish 
the task of maximizing efficiency while minimizing harmful effects. 
BACPT, 7-butyl-10-aminocamptothecin, was developed in an effort to improve potency 
and cross-resistance profiles in connection with the stability of the cleavage complex created 
when bound to the over expressed top I and DNA.54    BACPT is promising because it has been 
found that substitutions at the C-10 position on the molecule can increase lipophilicity, while 
substitutions at the C-7 position enhances potency in vitro.  BACPT is of particular interest 
because it exhibits increased activity at the acidic extracellular pH environment, which is 
common to many solid tumors.54,55  Large metastatic solid tumors usually have hypoxic 
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environments, which promote expression of stress response genes, tumor angiogenesis and drug 
resistance. 55,56,57  The cancer cell’s increased pHi (internal pH) causes cancer to spread by 
avoiding apoptosis, metabolic adaptation and directed cell migration.  The decreased pHe 
(extracellular pH) limits buffering, changes the extracellular matrix and enables tumor cell 
invasion. 19  Drug pKa has the ability to affect many biological processes: solubility, dissolution 
rate, reaction kinetics, formulation, cell permeability, tissue distribution, renal elimination, 
metabolism, protein binding and receptor interactions.58 
1.8 Paclitaxel 
Paclitaxel (PAC) is also a natural chemotherapeutic, isolated from the bark of the western 
yew tree. PAC has been established as having major effectiveness in the treatment of metastatic 
breast cancer, however it is also dose limited because it has low water solubility and can cause 
neurotoxicity and myelosuppression, amongst other complications. 59, 60, 61   The mechanism of 
PAC toxicity involves disruption of the microtubule system and blocking of cells in the late G2 
and M phases of the cell cycle. 62 
PAC has poorly water solubility and a broad tissue distribution profile, so it is normally 
delivered in Cremophor EL (a derivative of castor oil), ethanol and saline; a formulation which 
also carries toxicity. 62   With the FDA approval of Abraxane®, an HSAP with paclitaxel inside, 
the paclitaxel can be used at the most antitumor efficient doses without introducing further 
toxicity to the patient. 60, 63   Our hybrid particles seek to draw on the success of Abraxane with 
the addition of other treatment functionalities. 
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1.8 Renal Cell Carcinoma 
Renal cell carcinoma was as one of the most common malignancies in Europe and the 
U.S. as of  2008 and continues to make the list of most common cancers throughout the world. 1, 
64  There is a worldwide annual increase in incidence of about 2%, with an estimated 63,000 new 
cases predicted for the United States alone. 1, 64  The incidence of renal cell carcinoma (RCC) is 
usually asymptomatic and is mostly diagnosed during imaging examinations which are usually  
being performed for unrelated reasons. 65 
Surgery, where the diseased portion of the kidney is removed, has traditionally been the 
only curative therapeutic approach for renal cell carcinoma, with a focus on nephron-sparing 
techniques, if possible. 64  Deterioration in health, tumor size, age and tumor location do not 
always allow for the best surgical outcome.  Therefore, other treatment approaches have been 
developed to allow for minimum invasiveness. Treatment alternatives for RCC include 
percutaneous radiofrequency ablation (RFA), cryoablation, microwave ablation, laser ablation, 
and high intensity focused ultrasound ablation. 64  Potential advantages of these techniques 
include increased quality of life, the ability to treat high-risk surgical candidates and reduced 
complications caused by surgery. 64  Repeat ablation is necessary more frequently following 
RFA and local progression rates for cryotherapy and RFA are poorer than rates for surgical 
procedures. 64  However, if a treatment option possessed both the ability to ablate the RCC with 
more heating control and also contained a mechanism for temporal, controlled release of a 
proven RCC anticancer drug, such as sorafenib, the hybrid treatment could potentially eliminate 
the need for repeated ablation and allow for the non-surgical treatment of tumors larger than ~3 
cm.  
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Overall, the dual chemotherapeutic and heating therapies supplied by the hybrid 
nanoparticles described within this research are customizable and allow for: future drug 
combinations, controllable heating for direct ablation and increased induced drug uptake and 
contrasting and targeting amalgamations not previously seen in current clinical applications.   
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Chapter 2 
 Encapsulating Gold Nanomaterials into Size-Controlled Human Serum 
Albumin Nanoparticles for Cancer Therapy Platforms 
 
2.1 Abstract 
Progress has been made in using human serum albumin nanoparticles (HSAPs) as 
promising colloidal carrier systems for the early detection and targeted treatment of cancer and 
other diseases.  Despite this success, there is a current lack of multi-functional HSAP hybrids 
that offer combinational therapies. The size of the HSAPs has crucial importance on drug 
loading and in vivo performance and has previously been controlled via manipulation of pH and 
crosslinking parameters.  Gold nanomaterials have also gained attention for medicinal use due to 
their ability to absorb near-infrared light, thus offering photothermal capabilities.  In this study, 
the desolvation and crosslinking approach was employed to encapsulate gold nanorods, 
nanoparticles, and nanoshells into HSAPs.  Incorporation of gold nanomaterials caused some 
changes in HSAP sizes, but the general size trends remained.  This encasement strategy 
facilitated size-controlled HSAPs, in the range of 100-300 nm, loaded with gold nanostructures; 
providing composite particles which incorporate photothermally active components.  
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2.2 Introduction 
Some previous studies have focused on binding very small gold nanoparticles with HSA 
molecules, surface functionalizing a protein corona monolayer (dynamic surface layer) of HSA 
onto gold nanomaterials, and self-assembly of gold into AuNPs using HSA as the driving 
medium. 29, 37, 66, 67, 68   In the body a corona layer of proteins form on a nanoparticle surface 
when they are in contact with human biological proteins. These layers determine interactions 
with living systems and are responsible for cellular responses to the nanoparticles.  Coronas are 
composed of an inner layer (hard corona) and outer layer (soft corona).69   The inner layer is 
selected proteins with a lifetime of several hours.70  These manifest a slow exchange with the 
environment around them. The outer layer consists of weakly bound proteins and has a faster 
exchange with the environment.66,71  More biological impact comes from hard corona and their 
specificity and orientation for a receptor than from the soft corona, which are replaced quickly.66, 
72  Some studies on particles designed for intravenous use show there can be a suppressed 
immune responses because of these interactions.73   There has also been a variety of work on 
surface modifying drug-loaded HSAPs with other molecules such as biomarkers, fluorophores, 
and antibodies; however, the creation of an optimally-sized gold-HSAP functional hybrid is 
lacking. 8, 74, 75  
This research focuses on encapsulating the nano-sized gold described above into a shell of 
HSAP big enough to bind and hold an extremely high, maximum payload of drug, while 
succumbing to the enhanced permeability and retention effects that will cause it to be trapped in 
a cancerous matrix.  Also, the HSAPs should not induce such a detrimental corona response by 
biological proteins because it is seen by the body as commonplace as opposed to other capping 
agents that are put onto gold nanoparticles. Capping agents, such as CTAB 
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(cetyltrimethylammonium bromide), are becoming increasingly prevalent in nanoparticle 
synthesis and are primarily used to stabilize the highly reactive nanoparticle surfaces to 
aggregation and dissolution.76   Encapsulating otherwise unmodified gold nanomaterials in 
albumin will alleviate problems associated with the toxicity of capping ligands. 
 The novelty of this research is in successfully combining two proven treatment 
approaches: photothermally active gold nanomaterials with HSAP transporters of controllable 
size.  This research supplies promising template hybrids that could prove useful for future 
simultaneous, custom drug-loading and photothermal therapy.  We have created Au-HSAP 
hybrid composites with overall diameters of 125-300 nm as a proof of concept model that has a 
conceivable future as flexible, multimodal platforms for the detection and selective treatment of 
cancer and other diseases. 32, 77, 78, 79 
2.3  Experimental Methods 
2.3.1 Materials and Reagents 
Human serum albumin, lyophilized powder ≥ 97%, potassium bromide, and 8% aqueous 
glutaraldehyde were obtained from Sigma Aldrich (St. Louis, MO). Ethanol, 200-proof, 
ACS/USP grade was obtained from Pharmco-AAPER (CT, USA). Two types of spherical gold 
nanoparticles were prepared at the University of California, Santa Cruz: Approximately 28 nm 
diameter solid (still slightly porous) gold nanoparticles (2.4 × 1012 AuNPs/mL in water) and ~53 
nm outer diameter hollow gold nanoshells with ~4 nm thick shells (7.9 × 1010 AuNSs/mL in 
water). Both the AuNPs and AuNSs were created with a polyvinylpyrrolidone (PVP) coating that 
was used to drive the formation during the galvanic replacement of cobalt nanoparticles by Au3+ 
ions 80.   Phosphate buffer (pH 7.2) was obtained from VWR International (Radnor, PA). Water 
was distilled, deionized, and then further purified with a Barnstead Nanopure system. 
 15
Bare gold nanorods (10 nm average axial diameter, 43 nm average length, surface plasmon 
resonance ~ 808-829 nm, OD = 1, 5.9 × 1011 AuNR/mL in water) were obtained from Nanopartz, 
Inc. (Loveland, CO). The AuNRs used were advertised by the vendor as “bare”, but they did 
contain trace amounts of cetyltrimethylammonium bromide. To prepare a solution of 1.2 × 1013 
AuNR/mL, 2 mL of the original stock solution (5.9 × 1011 AuNR/mL) was centrifuged at 13,000 
RPM (16,060 g) for 1 hour until a pellet resulted. The pellet was dispersed in ~ 0.1 mL of water. 
The process was the same for creating a AuNR solution of 1.77 × 1013 AuNRs/mL from 3 mL of 
the original 5.9 × 1011 AuNR/mL gold solution.  
2.3.2 Synthesis of HSAPs and Au-HSAPs 
The HSAPs were prepared using a conventional desolvation technique. 6, 81, 82, 83  The 
standard method for preparation included the addition of 20 mg of solid HSA to 1 mL of water. 
After dissolving, the pH was around 7.  Any manipulation of pH was completed at this point by 
addition of 0.1 M NaOH (aq.).  A small stir bar was added to the solution, and 3 mL of 100% 
ethanol was added at a rate of 1 mL/min using a peristaltic pump. Upon addition of the ethanol, 
the solution became turbid.  Finally, 4.7 μL of 8% glutaraldehyde (aq.) was added to crosslink 
the HSA within the particles.  After 24 h of stirring, the particles were centrifuged at 13,000 
rpm (16,060 g) for 30 minutes to 1 hour.  The supernatant was removed and the remaining 
pellet was resuspended and washed twice with water. The particles were stored at 4 °C. In 
order to encapsulate gold nano-materials into the HSAPs, various amounts of gold 
nanomaterials were added to the aqueous albumin solution prior to addition of ethanol.   
The synthesis was also done in a scaled-down manner whereby the mass of HSA, 
volume of water, volume of ethanol, and amount of glutaraldehyde used were all reduced by 
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one-fourth to create smaller batches of HSAPs. Parameters used for preparing HSAPs with and 
without gold are provided in Table 2.1.
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Table 2.1. Preparation Parameters used to create HSAPs with and without gold nanomaterials. 
Sample HSA 
(mg) 
Water 
(mL) 
pH EtOH 
(mL) 
Aq. gold 
nanomaterial 
solution (mL) 
Theoretical 
Gold:HSA particle 
number ratioa 
Glutaraldehyde (μL 
of 8% aqueous 
solution) 
HSAP-1 20 1 7 3 None 0 4.7 
HSAP-2 20 1 8 3 None 0 4.7 
HSAP-3 20 1 9 3 None 0 4.7 
HSAP-4 20 1 7 3 None 0 9.4 
HSAP-5 20 1 9 3 None 0 9.4 
HSAP-6 5 0.25 7 0.75 None 0 9.4 (2% glutaraldehyde) 
AuNR-HSAP-1 5 0 7 3 1.0 AuNRb 1:1.5 2.4 
AuNR-HSAP-2 6 0 7 1.5 0.5 AuNRb 1:3.7 2.4 
AuNR-HSAP-3 2 0 7 5 2 AuNRb 3.2:1 2.4 
AuNR-HSAP-4 2 0 7 1.5 0.1 AuNRc 3.2:1 2.4 
AuNR-HSAP-5 5 0 7 3 0.1 AuNRd 1.9:1 2.4 
AuNP-HSAP-1 5 0.25 7 1.5 0.25 AuNPe 1:1.5 2.4 
AuNP-HSAP-2 5 0.25 7 2.25 0.5 AuNPe 1.3:1 4.8 
AuNP-HSAP-3 2.5 0.125 7 3 0.75 AuNPe 3.9:1 2.4 
AuNP-HSAP-4 2 0.1 7 3 0.9 AuNPe 5.9:1 2.4 (2% glutaraldehyde) 
AuNP-HSAP-5 0.5 0.025 7 3 0.95 AuNPe 25:1 2.4 
AuNP-HSAP-6 5 0 7 3 1.0 AuNPe 2.6:1 2.4 
AuNS-HSAP-1 5 0.25 7 1.5 0.25 AuNSf 1:46 2.4 
AuNS-HSAP-2 5 0.25 7 3.75 1.0 AuNSf 1:12 4.8 
AuNS-HSAP-3 2.5 0.125 7 3 0.75 AuNSf 1:7.7 2.4 
AuNS-HSAP-4 2 0.1 7 3 0.9 AuNSf 1:5.1 2.4 (2% glutaraldehyde) 
AuNS-HSAP-5 0.5 0.025 7 3 0.95 AuNSf 1:1.2 2.4 
aBased on all HSA forming 200 nm diameter spherical particles with d = 1.3 g/cm3; b5.9 × 1011 AuNR/mL;  
c1.18 × 1013 AuNR/mL; d1.77 × 1013 AuNR/mL; e2.4 × 1012 AuNP/mL; f7.9 × 1010 AuNS/mL 
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2.3.3 Density Separation 
 A potassium bromide solution was prepared by mixing ~75 g KBr with water (total 
solution volume was 100 mL) and stirring at 100°C for 4 hours. The density was calculated to 
be ~1.45 g/cm3.  AuNR-HSAPs were prepared via their respective parameters (Table 2.1) and 
centrifuged at 13,000 rpm for 1 hour to create a pellet. After removing the aqueous 
supernatant, 1 mL of the KBr solution was added to the pellet and the sample was 
homogenized by sonication for 10 seconds.  The particles resuspended in the aqueous KBr 
were then centrifuged at 13,000 rpm for 30 minutes to one hour.  The supernatant (containing 
any particles with a density of ~1.45 g/cm3or less) was removed from the red precipitate. 
Particles in the supernatant were washed several times by centrifugation with pure water.  The 
remaining red pellet from the KBr centrifugation was also washed several times with water. 
2.3.4 Absorbance 
 Absorbance measurements of the HSAPs and AuNS/NP/NR-HSAPs were performed 
with a Cary 60 absorbance spectrometer (Agilent Technologies).  
2.3.5 Dynamic Light Scattering 
The completed HSAPs were characterized by measuring the diameter and zeta potential 
using a Mobius dynamic light scattering (DLS) instrument (Wyatt Technology Corporation, 
Santa Barbara, CA).  Samples were diluted with water prior to analysis. 
2.3.6 SEM and TEM 
Particles were imaged using a field emission-scanning electron microscope FESEM, LEO 
1530VP (LEO Elektronenmikroskopie GmbH, Oberkochen, Germany). HSAPs were sputtered 
with a thin film of gold or silver to facilitate imaging. Transmission electron microscope (TEM) 
images were acquired with a JEOL Model 2010 TEM or with cryo-TEM using an FEI G2 F30 
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Tecnai TEM (FEI, Hillsboro, OR) with a Gatan-626 cryo-specimen holder and cryotransfer 
system (Gatan, Warrendale, PA). 
2.4 Results and Discussion 
2.4.1 HSAP Formation 
Desolvation is a simple, thermodynamically driven self-assembly process for polymeric 
materials by the addition of a denaturing agent, which coacervates the polypeptide molecules in 
the aqueous phase, thus facilitating electrostatic and hydrophobic interactions. 14,18  Because of 
this dependence on the attractive and repulsive forces, the pH of the HSA aqueous solution, as 
well as the amount of cross-linker added, play pivotal roles in the ultimate size of the formed 
particles.  Particle size also influences interactions of the particles with the cancer extracellular 
matrix. 14,19  Experiments were done to confirm preparation parameters, which have been 
previously well documented, that would yield 150-300 nm diameter unloaded HSAPs and to 
compare the preparation-based sizing trends to size outcomes of the gold-loaded HSAPs. Figure 
2.1 shows an FESEM image of HSAPs with no gold or drug loaded inside. 
 
Figure 2.1. FESEM image of 200-300 nm diameter HSA particles. 
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Experiments were done to find a starting pH that would yield 150-300 nm diameter HSAPs 
by adjusting the pH from ~6.8 – 10. Because the isoelectric point (pI) of HSA is ~4.7 to 5.4, it is 
not fruitful to try to form particles under pH 6. HSA has a zero net charge at these pH values, 
which causes unwanted, excessive aggregation of the particles and erratic size outcomes.  
Table 2.2. Averaged DLS data for HSAPs 
Sample Initial 
pH 
Theoretical 
% 
Crosslinked 
Diameter 
(nm) 
Polydispersity (%) ζ (mV) 
HSAP-1 7 40 248 ± 66 14 -14 
HSAP-2 8 40 151 ± 23 8 -27 
HSAP-3 9 40 140 ± 29 21 -28 
Error represents one standard deviation with N ≥ 3.  All reported diameters were statistically 
different at 95% confidence. 
 
Consistent with other literature reports, as the pH of the starting solution of HSA/water 
is increased, final HSAP size decreases, as seen in Table 2.2 and Figure 2.2. Note that Figure 
2.2 takes into consideration only those samples created with 20 mg HSA (see Table 2.1). The 
size decrease from ~248 ± 66 nm (at pH 7) to ~151± 23 nm (at pH 8) to ~140 ± 29 nm (at pH 
9) is likely due to an increase in net charge of the HSA molecules, which leads to the repulsion 
of HSA molecules and less aggregate formation. 20, 81, 83 
 At higher pH levels, the HSA became more negatively charged due to greater 
dissociation of protons at high pH, so smaller HSAPs were formed. The electrophoretic 
mobility (μE), the migration velocity per unit electric field) and the zeta potential (ζ, the 
electrokinetic potential of a molecule on its outer layer, slipping plane or diffuse layer), give 
insight into the charge and stability of the HSAPs as a colloid.84 The larger the zeta potential 
value is (either positive or negative), the more stable the colloidal system. As a rule of thumb, 
HSAPs are generally very stable as colloids at ζ > +25 mV or ζ < -25 mV, therefore it seems 
that the HSAP-2 (pH8) and HSAP-3 (pH9) particles with zeta potentials of -27mV and -28mV, 
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respectively, are more stable that the HSAP-1 (pH7) particles that have a zeta potential of -
14.84   
This desolvation process has the potential to theoretically make trillions of particles 
based on the average size of the particles created and the amount of milligrams of HSA used in 
the batch.  For example (assuming the density of the HSAP remains that of molecular HSA at 
1.31 g/cm3 and the average particle size created is 200 nm): taking into consideration the 
volume of the sphere, the mass per HSAP would be 5.48 × 10-12 mg.  If 20 mg of HSA powder 
was used (and all of it goes into making HSAPs), then 3.65 × 1012 HSAPs would be produced.  
It should be taken into consideration however, that when any preparation parameter is changed, 
such as starting pH, crosslinking level or mg HSA used, the number of particles created will be 
affected due to the change in size outcome. Also, a gold particle is present inside of an HSAP, 
it takes up space and volume, leaving HSA that would normally fill that space free to make 
even more HSAPs. Therefore, it is possible that when gold is present, even more HSAPs are 
created.  
 
Figure 2.2. Effect of initial pH on HSAP size with 20 mg HSA and 40% theoretical crosslinking 
(black bars) and 80% theoretical crosslinking (white bars). Data are from HSAP-1, HSAP-2, 
HSAP-3, HSAP-4, and HSAP-5. Error bars represent one standard deviation with N ≥ 3. 
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After ethanol is used to denature HSA, resulting in the formation of spherical HSAPs, 
glutaraldehyde is used as a cross-linking reagent to covalently crosslink the HSA acervates into 
place after aggregation. The amine groups of the 59 lysine residues, and the 23 arginine moieties 
in guanidino side chains on the HSA, are crosslinked by a condensation reaction with the 
aldehyde groups of glutaraldehyde. 20 It has been calculated that the lowest required amount of 
glutaraldehyde needed to quantitatively crosslink all 59 ε-amino groups present in 100 mg of 
HSA is approximately 58.8 μL of 8% (V/V) glutaraldehyde in H2O. 20 All theoretical 
crosslinking calculations were based on this previous work and it has been customary for groups 
working with this desolvation and crosslinking process to use percentage values to indicate 
crosslinking; even though it is essentially impossible to crosslink over 100% of the amino groups 
present on the HSA. 20, 85 Tables 2.2-2.5 list crosslinking percentages over 100%. This means 
that glutaraldehyde was added in excess as compared to the necessary theoretical amount to link 
all HSA amines to each other with a molecular glutaraldehyde linker. 
Previous studies have found that an increase in the glutaraldehyde crosslinker used 
leads to more stable HSAPs 11, 13.  That increase in stability leads to particles that are not as 
easily digested or broken apart. Even though there is no difference in cellular uptake with a 
change in crosslinking, a high degree of crosslinking is not ideal for easy release of the 
therapeutic elements inside.11, 13  We have found that there was a decrease in average diameter 
from 140 ± 29 nm to 96 ± 11 nm for particles created at pH 9 when the mole ratio of  
glutaraldehyde:HSA was doubled from ~12.7 to 25.4 (hallow bars in Figure 2.2).  The zeta 
potential showed increases from -14, -27 and -28 mV (for HSAP-1, HSAP-2, and HSAP-3, 
respectively) to -35 and -30 mV (for HSAP-4 and HSAP-5, respectively) when the amount of 
crosslinking agent was increased. 
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2.4.2 HSAP Formation: Reagent HSA Effects 
The above mentioned preparation effects on size trends are well documented, however 
there was one interesting experimental outcome that had not previously been found in the 
literature: the effects of the starting mass of HSA on the size outcome. In an effort to minimize 
consumption of starting materials, the amount of each reagent was cut by one-fourth: 5 mg of 
HSA was dissolved into 0.25 mL of water and 0.75 mL of ethanol was delivered, followed by 
2.36 μL of 8% aqueous glutaraldehyde (1.9 × 10-6 moles). It was noticed that decreasing the 
amount of reagents used caused a change in HSAP size and zeta potential. Despite preservation 
of mole ratios, there was an unexpected decrease in observed HSAP size with smaller batches 
(compare HSAP-6 to HSAP-4 in Table 2.2). At 80% theoretical crosslinking, the average 
diameter of HSAPs created at pH 7 in the original 20 mg HSA batch was 220 ± 25 nm, but the 
average diameter of the same type of particles created in a 5 mg batch was 135 ± 3 nm. 
Since the starting mass of HSA had an effect on the size of the resulting nanoparticles, 
careful attention must be paid to parameters during scale-up for manufacturing purposes or even 
for preclinical and/or clinical research85. This size effect may be due to changes in the number of 
nucleation sites. 
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Table 2.3. Particle size and zeta potential data for AuNR-HSAPs. 
Sample Theoretical % Crosslinked Diameter (nm) Zeta Potential (mV) 
AuNR-HSAP-1 80 222 ± 5a -20 
AuNR-HSAP-2 80 262 ± 20 -13 
AuNR-HSAP-3 200 190 ± 1 -19 
AuNR-HSAP-4 200 119 ± 4 -91 
AuNR-HSAP-5 80 152 ± 20 -23 
aError represents one standard deviation with N ≥ 3.  All reported diameters were statistically 
different at 95% confidence. 
 
2.4.3 Formation of Composite Au-HSA Particles 
The aim of this project was to create Au-HSA composite particles for potential future use 
in photothermal therapy. We utilized three separate types of gold nanomaterials: rods, spheres 
and shells.  Empty HSAPs created with 5 mg of HSA in 0.25 mL of H2O with addition of 0.75 
mL of EtOH and crosslinked with 9.4 μL of 2% glutaraldehyde yielded samples with a size of 
135 ± 3 nm, therefore it was assumed that the AuNS-HSAPs and AuNP-HSAPs created under 
similar desolvation parameters would yield roughly the same particle size. That hypothesis 
proved correct. The protocol followed that of forming unloaded HSAPs (Section 2.4.1) 
however, Au nanomaterials were dispersed in aqueous albumin solutions prior to coacervation 
of the albumin.  Because gold is readily coordinated by amines and other functional groups in 
the albumin, we expected the albumin to coat the surface of the gold prior to coacervation, 
resulting in the gold particles acting as nuclei for coacervation.  We utilized several approaches 
to prove that the Au and HSA particles were in fact associated. 
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The ratio of gold particles to albumin particles was calculated for each preparation (see 
Table 2.1). For example, using the AuNR-HSAP-1 preparation method, if all 5 mg of HSA 
formed spherical particles with an average size of 200 nm, then the process was capable of 
creating 9.13 ×1011 HSAPs (assuming the HSAPs have a density equal to that of molecular 
HSA, 1.31 g/cm3).  Adding 1 mL of AuNR solution to the HSA would yield a AuNR:HSAP 
ratio of ~ 1:1.5.  This means ~ 66% of the particles would be loaded with a gold nanorod if 
encapsulation were perfect. 
 Extensive analysis of multiple Au-HSAP samples by TEM and cryo-TEM revealed only 
Au-HSAP and unloaded HSAP particles; free gold particles were observed only in rare cases. 
(Representative figures for AuNR-HSAPs, AuNP-HSAPs and AuNS-HSAPs are shown later in 
this chapter.)  In every case where both Au and HSA particles were co-located, the Au was 
fully within the outer boundary of the HSA particle; completely encapsulated into the HSA.  
It is worth noting that the sample preparation is different for cryo-TEM and conventional 
TEM imaging. In the case of cryo-TEM, the samples are freeze dried; thus the cryo-TEM 
samples avoided the agglomeration that was apparent for the conventional TEM observations. 
In addition, heating from the intense electron beam in the conventional TEM likely cause some 
melding (aggregation) of the Au-HSAPs, since the proteins are highly affected by the heat.  
Such issues were avoided in cryo-TEM by cooling the sample during imaging. 
2.4.4 Formation of Composite AuNR-HSA Particles 
 AuNR-HSAPs were formed using the preparation parameters in Table 2.1. In order to 
confirm that the AuNRs and HSA were actually encapsulated, we performed a centrifugal 
separation using a 1.45 g/cm3 liquid medium (concentrated aqueous KBr).  This separation 
resulted in two types of red materials: 1) material that precipitated (d > 1.45 g/cm3) and 2) 
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material that remain suspended (d < 1.45 g/cm3).  The red color of these materials was due to 
gold.  Unloaded HSAPs are white or faint yellow in color, but never red.  Free gold, with a 
density of 19.3 g/cm3, would have precipitated completely in this system.  The suspended red 
material contained gold and had a density of less than 1.45 g/cm3.  The only explanation for 
this result is that the gold was encapsulated into an albumin particle with low density, so that 
the average density of the composite particle was less than 1.45 g/cm3.  For a 200 nm diameter 
spherical HSAP with a single 10 nm diameter × 43 nm long gold nanorod, the density would 
be ~1.32 g/cm3.  These composites would therefore remain suspended in the KBr solution upon 
centrifugation.   
We visualized the supernatant and the red precipitate from this centrifugal separation using 
TEM.  Images of what was found in the supernatant are presented later in Figures 2.7a thru e.  
Although some unloaded-HSAPs were observed by TEM in the supernatant, numerous 
particles with nanomaterials inside them were observed.  These observations are consistent 
with the conclusion that the gold was loaded into albumin particles. The precipitate consisted 
of aggregated HSAPs with multiple gold nanoparticles loaded inside of them (see Figures 2.3 
a. and b.).   
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Figure 2.3. TEM images of AuNR precipitate layer after density separation for (a) AuNR-
HSAP-1 (Inset: the image is further magnified) and (b) AuNR-HSAP-5. 
 
Because of the high gold loading, these particles had a large density and were precipitated 
in the centrifugation.  No free gold nanoparticles were observed in the precipitate, suggesting 
that gold particles served as nuclei for albumin coacervation.  This conclusion is reasonable 
since free albumin is known to bind strongly to gold. 71 Further evidence that the gold was 
encapsulated in the albumin was provided by absorbance measurements.  We collected the 
absorbance spectrum of the supernatant from the centrifugal separation and compared this 
spectrum to that of free AuNRs in aqueous solution.  The spectra are presented in Figure 2.4.   
 28
 
Figure 2.4. Absorbance of AuNR-HSAP-3 loaded particles (solid line) and a stock solution of 
free AuNRs with a concentration of 8.31 × 1010 AuNRs/mL (dashed line). 
 
The AuNR-HSAP spectrum was background subtracted to eliminate absorbance and 
scattering signals from the HSAP, and considerable noise is present.  Nevertheless, signals for 
both the transverse and longitudinal Au localized surface plasmon resonances (LSPR) are 
clearly visible near 540 and 850 nm.  These peaks are shifted considerably from the peaks for 
free AuNR (520 nm for transverse axis LSPR and 800 for longitudinal LSPR).  Such shifts are 
expected when the surface of the gold has strong interactions with other materials. 30, 66  
Because of the large shifts in the LSPR and the high likelihood of concurrent changes in 
absorptivity, we did not perform quantitative measurements by absorbance to determine the 
amount of gold trapped in these particles. 
A final test to prove association of the gold with the HSAPs involved measurement of 
particle size and zeta potential.  We compared these parameters for free AuNRs, AuNR-HSAPs 
(as collected from the KBr supernatant) and unloaded HSAPs.  The observed hydrodynamic 
diameters for these samples were 57 ± 7 nm, 219 ± 13 nm, and 220 ± 25 nm, respectively.  The 
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AuNR-HSAP showed a particle size distribution similar to that of unloaded HSAP, and the 
AuNR-HSAP sample had no evidence of particles with diameters corresponding to free AuNR 
(see Figure 2.5).   
 
Figure 2.5. Particle size distributions for (a) free AuNRs, (b) gold-loaded HSAPs created 
via the AuNR-HSAP-1 method, and (c) unloaded HSAPs. 
 
Consequently, the light scattering measurements support the conclusion that the gold in the 
AuNR-HSAP sample was not free. The measured zeta potential of the free AuNRs, AuNR-
HSAPs and the unloaded HSAPs were -4.0 ± 1, -30 ± 8 and -35 mV, respectively. The gold 
loaded albumin particles and unloaded albumin particles had zeta potential values that were 
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indistinguishable and much greater than free gold particles, suggesting that the gold particles 
were encapsulated in the albumin. 
 
 
Figure 2.6. : a) FESEM image of AuNR-HSANP-1 with a gold rod visible at the surface (see 
arrow).  Tips of other rods may also be visible (light regions on particles) and b) TEM image of 
AuNR-HSANP-2 particles with a gold rod visibly surrounded by a layer of albumin 
 
Taken together with the TEM images and the absorbance data presented above, the particle 
size and zeta potential data further confirm that the gold was associated with albumin particles 
and was not present as free nanorods. Additional inspection of an FESEM image in Figure 2.6a 
reveals a rod apparently positioned on its axial side, protruding down into the HSAP.   
Evidence of HSAP particle deformation is visible in Figure 2.6b in which the HSAP shape 
conforms to the outline of the AuNR at the edge of the albumin particle.  There is also 
evidence of multiple rods being loaded into one HSAP (Figure 2.8a thru e); some with 
nanorods apparently both parallel and perpendicular to the plane of view (Figure 2.8d and 
2.8e).  With a limited amount of gold nanoparticles, loading multiple gold particles into each 
albumin particle further decreases the chance of each albumin particle being loaded with a gold 
particle.   
  b. a. 
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Figure 2.7. Cryo-TEM images of singly loaded AuNR-HSAPs from (a) AuNR-HSAP-1; (b and 
c) AuNR-HSAP-2 and (d and e) conventional TEM images of AuNR-HSAP-3. 
 
Figure 2.8. (a, b and c) Conventional TEM images of AuNR-HSAP-3; (d) cryo-TEM image of 
AuNR-HSAP-1 (e) and cryo-TEM image of AuNR-HSAP-2. All images show particles with 
multiple gold rods trapped within the HSAP. 
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Table 2.3 presents the particle size and zeta potential data for the AuNR-HSAPs.  The 
observed diameters were between 119 ± 4 and 262 ± 20 nm and varied depending on the 
preparation parameters. As the amount of HSA decreased, the particle size decreased as well. 
The zeta potentials for these particles were all negative, but were slightly smaller than desired to 
maintain a stable colloid without aggregation. To combat this, further ultrasonication is needed 
to break up particle aggregation after the heavy centrifugation technique used in the density 
separation. 
  It is evident that the loading ratio of AuNRs:HSAPs determined through theoretical 
calculations (Table 2.1) were not represented in the ultimate formed particles.  This discrepancy 
is partially due to the fact that HSAPs are capable of loading multiple rods, which was 
unexpected and opportune. In addition, loading a nanorod into an HSAP takes up a volume of 
space and therefore, decreases the amount of molecular HSA in that particle, freeing it for the 
formation of additional HSAPs. Third, the calculations were based on an average HSAP size of 
200 nm, however when the average particle size decreases, many more HSAPs are formed. 
The lack of gold in some of the particles did not seem to affect other characteristics of the 
particles, as the morphology remained spherical (aside from any slight changes to the albumin 
shape to accommodate encapsulated gold particles).  The sizes remained within the expected 
range, and the zeta potentials remained negative, indicating stability. The presence of the gold 
did not increase aggregation of the particles. As proven via the density gradient study, free 
AuNRs could not be found. Every AuNR found using microscopy was in some way associated 
with an HSA coating, therefore the efficiency of gold incorporation can be said to be close to 
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100%. However, the distribution was not completely uniform.  Some AuNR-HSAPs were 
formed with six rods encapsulated, while some HSAPs formed with no rods encapsulated.  
The AuNR-HSAP-3 preparation method (containing 2 mg HSA and 2 mL AUNR stock 
solution) was the most successful method in this trial, yielding the greatest extent of albumin 
particles loaded with gold (see Figure 2.9).  This result illustrates that adjusting the formation 
parameters can control the gold loading and particle size.  However, additional work is needed to 
further optimize the particle characteristics.  
 
Figure 2.9. TEM image of particles created via the AuNR-HSAP-1 method with increased 
loading of AuNRs; illustrating the non-uniformity of loading. There is some melding of particles 
present due to the heating from the electron beam. 
 
2.4.5 AuNS-HSAPs and AuNP-HSAPs Formation 
Unloaded, HSAPs created with 5 mg of HSA in 0.25 mL of H2O with addition of 0.75 mL of 
EtOH and crosslinked with 9.4 μL of 2% glutaraldehyde (aq.) yielded samples with a size of 135 
± 3 nm.  Particle size measurements for composite particles revealed an average diameter of 156 
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± 15 nm for AuNS-HSAP-1 and 195 ± 9 nm for AuNP-HSAP-1.  These particles remained under 
200 nm in average diameter, an effective size range for use as a treatment vehicle. Tables 2.4 and 
2.5 show the size and zeta potential information for the AuNS and AuNP loaded HSAPs, 
respectively.  These particles are slightly smaller compared to an average of 245 ± 66 nm for 
unloaded HSAPs. 
 
Table 2.4. Particle size and zeta potential data for AuNS-HSAPs. 
Sample Theoretical 
% 
Crosslinked 
Diameter 
(nm) 
Zeta 
Potential 
(mV) 
AuNS-HSAP-1 80 156 ± 15a -26 
AuNS-HSAP-2 160 102 ±1 -20 
AuNS-HSAP-3 40 109 ± 4 -17 
AuNS-HSAP-4 50 54 ± 2* -26 
AuNS-HSAP-5 800 51 ± 1* -18.5 
aError represent one standard deviation with N ≥ 3. All reported diameters were 
statistically different at 95% confidence except those noted by *. 
 
Table 2.5. Particle size and zeta potential data for AuNP-HSAPs. 
Sample Theoretical 
% 
Crosslinked 
Diameter 
(nm) 
Zeta 
Potential 
(mV) 
AuNP-HSAP-1 80 195 ± 9 -25 
AuNP-HSAP-2 160 109 ± 1 -35 
AuNP-HSAP-3 40 122 ± 1 -16 
AuNP-HSAP-4 50 86 ± 1 -27 
AuNP-HSAP-5 800 67 ± 1 -17 
aError represents one standard deviation with N ≥ 3. All reported diameters were 
statistically different at 95% confidence. 
 
Figure 2.10a presents a cryo-TEM image of hybrid particles from AuNS-HSAP-2, clearly 
illustrating that the gold particles were encapsulated with albumin particles. There is also 
evidence of individual AuNS-HSAPs incorporating more than one gold nanoshell. Figure 2.10b 
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presents a cryo-TEM image of AuNP-HSAP-1, where some albumin particles do not have gold 
inside.  The ratio of AuNP to HSAP in this batch was approximately 1:1.5, indicating that the 
AuNP were present as a limiting reagent.  Consequently, it is not surprising that we observed 
numerous unloaded HSAPs (not depicted) and no evidence of free AuNPs. 
 
Figure 2.10. Cryo-TEM images of (a) AuNS-HSAP-2 and (b) AuNP-HSAP-1. 
Figure 2.6: Cryo-TEM images of (a) AuNS-HSAP-2 and (b) AuNP-HSAP-1. 
As seen in Tables 2.4 and 2.5, the average particle size and zeta potential observed for 
the various AuNP-HSAP and AuNS-HSAP preparations followed similar trends, suggesting 
that the preparation parameters can be generalized to the incorporation of any type of gold 
nanoparticle.  For both AuNS-HSAPs and AuNP-HSAPs, increasing the extent of crosslinking 
resulted in smaller particles.  This result is consistent with that of unloaded HSAPs, as 
previously discussed.  For both AuNS and AuNP loading in Figures 2.10a and 2.10b, it is 
believed that insufficient gold particles were present to achieve complete loading of the 
albumin particles (due to the freeing of HSA when a gold particle takes up volume), and no 
evidence of free AuNPs or AuNSs was observed after extensive TEM observation.  
For the purpose of creating a particle with high drug payload capacity and large ligand 
binding capabilities, the particle size distribution of AuNP-HSAP-5 (Figure 2.11) samples should 
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still prove sufficient, as it still had substantial HSAP volume around the gold and high surface 
area per gram due to the smaller particle size. The solid gold particles were roughly 10-30 nm, 
and the resulting AuNP-HSAPs were on average 67 ± 1 nm; that is a diameter increase of ~55 to 
85%, which verifies the albumin coating as substantially more than a monolayer of HSA 
surrounding the gold.  Thin HSA coatings (less than 15 nm thick) on gold nanoparticles have 
previously been reported as corona layers. 29, 37, 67, 68 However, those particles would not have the 
same drug loading capacity as those produced in this study due to the thicker coating of HSA 
achieved here. 
 
 
Figure 2.11. TEM image of AuNP-HSAP-5 particles created with less HSA. 
 
2.5 Conclusions 
In this study, composite AuNP-HSAPs, AuNS-HSAPs, and AuNR-HSAPs were successfully 
prepared as a proof of concept to show that these composite particles can serve as platforms for 
preparing new drug therapies. This research has shown that size-controlled encasement of these 
gold nanomaterials into larger (100-300 nm) HSAPs is possible via a desolvation and 
crosslinking process. Moreover, the same preparation parameter manipulations that allow for 
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controllable particle size of medicinally useful HSAPs are in operation when the procedure is 
conducted with gold nanomaterials present. One new development regarding the preparation 
process for making unloaded HSAPs is that the starting mass of HSA plays a role is the size 
outcome. Since the ultimate goal is effective treatment of cancer cells via targeted drug delivery 
and photothermal therapy, simultaneously loading of HSAPs with both gold nanomaterials and 
an appropriate drug is a future direction for these studies.  The combined approach will allow 
killing of cancer cells by both hyperthermia and localized chemotherapy treatment and is more 
likely to eliminate all cancer cells.   
In addition, the photothermal approach may serve as a trigger for drug release once the 
particles have reached their targeted tissue.  Functionalizing the surface of the HSAPs with 
disease-specific targeting ligands may lead to even more effective delivery of cancer therapies to 
the site of the disease, boosting effectiveness and reducing damage to healthy tissue. 86 The 
optimal number of gold nanoparticles loaded into each HSAP to achieve effective hyperthermic 
treatment is not yet known, but is the subject of ongoing studies, as is improving the control of 
AuNP loading efficiency.  Furthermore, the effect of radiative heating of gold nanomaterials in 
HSAPs on the release of simultaneously encapsulated drugs also needs additional study.  
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Chapter 3  
Hybrid Gold Nanorod-Human Serum Albumin Nanoparticles for 
Simultaneous Chemotherapeutic and Photothermal Therapy Platforms 
 
 
3.1 Abstract 
Human serum albumin nanoparticles (HSAPs) as drug carrier systems for treatment of 
cancer have proven successful through current marketable clinical formulations. Despite this 
success, there is a lack of multi-functional HSAP that offer combinational therapies from more 
than one proven technique. Gold nanorods (AuNRs) have also shown medicinal promise due to 
their photothermal therapy capabilities. In this study, the desolvation and crosslinking approach 
was employed to successfully encapsulate gold nanorods into HSAPs along with incorporation of 
the chemotherapeutic drug paclitaxel (PAC), forming PAC-AuNR-HSAPs with desirable overall 
particle sizes of 299 ± 6 nm. The loading efficiency of paclitaxel into PAC-AuNR-HSAPs 
reached up to 3μg PAC/ mg HSA.  The PAC-AuNR-HSAPs experienced photothermal heating, 
with bulk solution temperatures reaching up to 46 ˚C after 15 minutes of near-IR laser exposure, 
indicating successful attainment of the temperature necessary to cause severe cellular 
hyperthermia and necrosis.  
This encasement strategy facilitated a colloidal hybrid treatment system capable of  
enhanced permeability and retention effects, photothermal ablation of cancer cells, and release of 
the active paclitaxel of up to 188 ng (from PAC-AuNR-HSAPs created with 30 mg HSA) in a 
single 15 minute irradiation session. The system also lends itself to future customizable external 
functionalities via conjugated targeting ligands such as antibodies. Internal entrapment of patient 
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tailored medication combinations are also possible with this combination treatment platform, 
which may result in improved quality of life for those undergoing treatment. 
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3.2	Introduction	
There is a current need for multi-functional, temporally active cancer treatments which 
maximize therapeutic effects through less invasive techniques.  A hybridization of effective 
treatments can offer combinational therapy, which may result in higher success rates and 
increased quality of life for patients suffering with the disease.  Gold nanorods (AuNRs) have the 
ability to absorb relatively harmless near infrared light, causing the subsequent release of energy 
via heat, which can be harnessed for use in plasmonic photothermal therapy (PPTT). 22, 34, 35, 86 
Moderate cell hyperthermia occurs at 43˚C and can cause increases in endocytosis and 
blood flow, resulting in not only an increase in uptake of drugs, but a breakdown in cellular 
structure.26  Increasing the induced temperature to over 46˚C will cause severe hyperthermia and 
eventual cell death through heat ablation.27  This dose-controllable heat therapy shows 
immediate anticancer effects; however, the full benefits are hindered due to the distribution of 
power within the beam and the gradual reduction of heat in the tissues farther from the AuNR.28 
Therefore, developing a hybrid mechanism to also carry a proven chemotherapeutic drug along 
with the AuNRs, with long-lasting staying power is desirable. 
In a previous study, we focused on a proof-of-concept synthesis to fully encapsulate gold 
nanorods into HSAP spheres to harness their PPTT effects; with the goal of keeping them from 
being susceptible to clearing the body as fast as smaller, drug-conjugated AuNRs prepared by 
other researchers.41, 87  Human serum albumin (HSA), the most abundant human blood protein, 
offers biocompatibility, biodegradability, and the ability to conjugate drugs and other organic 
and inorganic substances via covalent and non-covalent attachment to its many functional 
groups.17, 3 When aggregated together via a desolvation and crosslinking technique, HSA forms 
nanoparticles (HSAPs).  
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These HSAPs have previously been surface modified for diagnostic and targeting 
functions and utilized in controlled release studies, due to enhanced permeability and retention 
effects (EPR); where particles of certain sizes accumulate at tumor sites. 5, 8, 9  Our previous 
approach allowed for internal binding to the HSA hydrophobic pockets as well as external 
surface functionalizing of the HSAPs, even with AuNRs present. The HSAPs are largely capable 
of binding a multitude of biomarkers, fluorophores, antibodies, etc.  Because the HSAP are 
larger than the individual gold particles, the HSAP can bind more materials than bare AuNRs 
alone .74, 75, 88, 8 
Paclitaxel (PAC) is a natural chemotherapeutic agent isolated from the bark of the 
western yew tree. PAC has been established as having major effectiveness in the treatment of 
metastatic breast cancer; however, it is dose limited because it has low water solubility and can 
cause neurotoxicity and myelosuppression amongst other complications.59, 60, 61  Paclitaxel-filled 
HSAPs have been proven as safe medical transporters as used in the clinical formulation 
AbraxaneTM; which has been successful in the treatment of lung, ovarian, breast, head and neck 
cancer.63  With the FDA approval of Abraxane®, paclitaxel can be used at the most antitumor 
efficient doses without introducing further toxicity to the patient.60 
In 2013, Abraxane was also approved for use in treating pancreatic cancer as a less toxic 
alternative to folfirinox and it is expected to become the standard of care for pancreatic cancer.89, 
90, 91  The “nab-paclitaxel” particles (nanoparticle albumin-bound) allow for transport of toxic or 
low solubility drugs with high loading efficiency, good storage competence, and minor 
leakage.11, 15,  Our approach utilizes this up-and-coming particle formulation and improves its 
treatment potential with the option of controlled heating: at lower induced temperatures, drug 
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uptake is facilitated and at higher induced temperature, complete cancer cell ablation is 
possible.92 
The goal of this study was to substantiate the theory that proven anticancer drugs, such as 
PAC, could also be effectively housed within the AuNR-HSAPs, with efficient loading.  
Subsequently, adequate PAC release via the PPTT heating of the hybrid particles was also 
necessary for immediate additive treatment effects.  This research supplies evidence that the 
PAC-AuNR-HSAP hybrid delivery system offers simultaneous drug-release and PPTT as well as 
extended, controlled further release of the drug over time.  The PAC-AuNR-HSAPs have the 
potential to be irradiated in the biologically safe water window (700-900 nm) in vivo at a tumor 
site up to 10 cm below the skin without affecting surrounding healthy cells. 28, 93   
This work shows drug-Au-HSAP hybrid composites with overall diameters of 299 ± 6 nm, 
which have a conceivable future as flexible, multimodal platforms for the targeted detection, 
contrast imaging and selective treatment of cancer and other diseases.32, 77 
3.3 Experimental Methods 
3.3.1 Materials and Reagents 
Human serum albumin, lyophilized powder ≥ 97%, potassium bromide, Acrodisc® syringe 
filters with nylon membrane (diam. 13 mm, pore size 0.2 μm), Corning Costar cell culture plates 
(flat bottom, 12 well), and 8% aqueous glutaraldehyde were obtained from Sigma Aldrich (St. 
Louis, MO). Ethanol (200-proof, ACS/USP grade) was obtained from Pharmco-AAPER (CT, 
USA). Water was distilled, deionized, and then further purified with a Barnstead Nanopure 
system.  
Bare gold nanorods (10 nm average axial diameter, 43 nm average length, surface plasmon 
resonance ~ 808-829 nm, OD = 1, 5.9 × 1011 AuNR/mL in water) were obtained from Nanopartz, 
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Inc. (Loveland, CO). The AuNRs used were advertised by the vendor as bare, but they did 
contain trace amounts of cetyltrimethylammonium bromide.  
3.3.2 Synthesis of PAC-AuNR-HSAPs and PAC-HSAPs 
The PAC-AuNR-HSAPs were prepared using a conventional desolvation technique  
with the addition of AuNR seeding and drug loading. 20, 81, 83  The standard method for 
preparation included creating an aqueous HSA stock solution (100 mg/mL).  After dissolving, 
the pH was around 7.  To a portion of the HSA stock solution, an aliquot of the AuNR stock 
solution was added, along with a small stir bar. From a paclitaxel stock solution (1 mg /mL 
ethanol), an aliquot was added drop-wise to the AuNR/HSA solution flask at a rate of 1 
mL/min using a peristaltic pump. Then, additional ethanol was added to achieve a final 
solution containing 60% ethanol. Upon the addition of the ethanol, the solution became turbid.  
Finally, an aliquot of 8% glutaraldehyde (aq.) was added to crosslink the PAC-AuNR-HSAPs. 
After 24 h of stirring, the particles were centrifuged at 13,000 rpm (16,060 g) for 20 minutes. 
The supernatant was removed, filtered using a 0.2 µm syringe filter and saved for HPLC 
analysis. The remaining particle pellet was resuspended in a wash solution of 2:3 water:ethanol 
via ultrasonication. The particles were washed twice using 2:3 water:ethanol and the 
supernatants were saved for HPLC analysis. The washed particles were stored at 4 °C in water. 
The PAC-HSAPs were created by the same process as the PAC-AuNR-HSAPs, with an aliquot 
of pure water substituted for the AuNR stock solution. 
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3.3.3 HPLC 
The HPLC system used to analyze the paclitaxel was an Agilent 1100 instrument (Palo Alto, 
CA) with a diode array absorbance detector.  The column was an Agilent Eclipse XDB-C18 
column (150 X 4.6 mm, particle size 5μm). The injection volume was 100 μL, and the 
wavelength used for quantitation was 227 nm. The solvent mobile phase was 45% acetonitrile 
and 55% water at a flow rate of 1 mL/min. The elution time for the PAC was approximately 3.8 
minutes.  Total entrapment of the drug was determined as the total mass of drug added to the 
particles minus the combined mass of drug in the supernatant and washes. 
3.3.4 Dynamic Light Scattering 
The HSAPs were characterized by measuring their diameter, mobility, and zeta potential 
using a Mobius dynamic light scattering (DLS) instrument (Wyatt Technology Corporation, 
Santa Barbara, CA).  Samples were diluted with water prior to analysis. 
3.3.5 Laser Irradiation of Particles 
The PAC-AuNR-HSAPs and PAC-HSAPs were tested for heating ability and drug release 
under laser irradiation. To heat the samples, 1 mL of the sample was placed into a well of a 12-
well plate. The plate was placed approximately 4 inches under a vertically mounted laser. A 
LabSpec 808 nm collimated diode laser system was used at a continuous wave power output of 
2000 mW for 15 or 30 minutes for each sample. The size of the beam was approximately 1 × 1 
cm.  Temperature changes caused by the irradiation sessions were measured using a Spark 
Science Learning System™ model PS-2008A thermocouple.  
After irradiation, the contents of the wells were collected and centrifuged at 13,000 RPM for 
15 minutes. The resulting supernatant was collected, diluted with ethanol, filtered, and saved for 
HPLC analysis. 
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3.3.6 SEM and TEM 
Particles were imaged using a field emission-scanning electron microscope FESEM, LEO 
1530VP (LEO Elektronenmikroskopie GmbH, Oberkochen, Germany). HSAPs were sputtered 
with a thin film of gold or silver to facilitate imaging. Transmission electron microscope (TEM) 
images were acquired with a JEOL Model 2010 TEM. 
3.4 Results and Discussion 
3.4.1 Formation of PAC-HSAPs and PAC-AuNR-HSAPs  
Desolvation is a simple, thermodynamically driven self-assembly process for polymeric 
materials by the addition of a denaturing agent, which coacervates the polypeptide molecules in 
the aqueous phase, thus facilitating electrostatic and hydrophobic interactions.14  DLS confirmed 
that the average particle sizes for PAC-HSAPs with no AuNRs inside (using 30 mg HSA) was 
158 ± 7 nm and PAC-AuNR-HSAPs were 331 ± 3, 299 ± 6 and 212 ± 28 nm when starting the 
preparation process with either 20, 30 or 50 mg HSA, respectively (while all other preparation 
parameters were held constant). When AuNRs were present, the overall average HSAP size 
increased; likely due to the AuNRs acting as seeds, taking up internal space in the HSAP, thus 
facilitating more HSA available for continued particle growth.  
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Figure 3.1. AuNR-HSAPs created with 2 mg of HSA and 2 mL of AuNR stock solution 
visualized via (a) FESEM image and (b) TEM image showing the AuNRs within. 
 
There was also a trend of decreasing AuNR-HSAP size as the amount of protein available 
was increased from 20 to 30 to 50 mg. This size decrease is likely due to the fact that more HSA 
present allows for continued new particle formation after all AuNRs have been encapsulated; 
thus creating a greater number of smaller unloaded-HSAPs and a smaller average particle size. 
Therefore, the AuNR-HSAPs present are smaller overall, but with more polydispersity.  
Figure 3.1 provides representational SEM and TEM images of the AuNR-HSAPs created 
with only 2 mg of HSA and 2 mL AuNR stock solution.  (For imaging purposes, more heavily 
a.  
b.  
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AuNR loaded particles with larger sizes are shown here, whereas the same amount of AuNRs 
loaded into 20, 30 or 50 mg of HSA would result in a TEM image of largely unloaded-HSAPs 
amongst the AuNR-HSAPs.) The PAC-AuNR-HSAPs created with either 20, 30 or 50 mg of 
HSA had zeta potential values of ζ = -38 ± 1, -42 ± 3 or -45 ± 3 mV, respectively; showing 
highly stable particle formations; since colloids are generally very stable when ζ > +25 mV or ζ 
< -25 mV.  
Aside from EPR effects mentioned previously, studies have shown that albumin-bound 
paclitaxel binds to the gp60 HSA receptor on the cell surface, facilitating transcytosis via the 
formation of caveolae; thus causing increased uptake of PAC into diseased cells.94  Our 
formation of bio-friendly particles are not only efficiently sized for EPR effects, but they also 
have the potential to mitigate damage to healthy cell membranes caused by toxic CTAB-coated 
AuNRs.95  Since any residual CTAB is hidden by the HSAP shell, the toxicity caused by CTAB 
should be reduced. 
3.4.2 Loading Efficiency of PAC  into HSAPs and AuNR-HSAPs 
The aim of this project was to create PAC-AuNR-HSAP composite particles for potential 
future use in PPTT.  Because gold is readily coordinated by sulfur-containing moieties in the 
albumin (resulting in Au-albumin thiol bonds), we, and other researchers, have previously seen 
that the albumin coats the surface of the gold.95, 96  This protein corona layer results in the gold 
particles which act as nuclei during coacervation of the AuNR-HSAPs.   
To test whether the presence of AuNRs hindered the drug encapsulation ability of the 
HSAPs, 0.5 mg of PAC was added to separate particle batches consisting of either 30 mg of 
HSA or 30 mg HSA and 1.5 mL AuNRs solution. It was found that the PAC-HSAPs and the 
PAC-AuNR-HSAPs entrapped an average of 63.3 ± 14 and 91.8 ± 9 µg of PAC, respectively. 
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There was a 45% increase in PAC loading when AuNRs were present in the particles. This was a 
surprising result and it is not fully known what caused this increase in PAC loading when 
AuNRs were present.   
We speculate that the PAC could have adsorbed onto the AuNRs (due to a hydrophobic 
interaction with the trace CTAB present) prior to and during the formation of the HSA corona 
layer.  Previous research has shown that the ammonium group of one CTAB binds to the surface 
of the gold and the hydrocarbon chain can interact with another CTAB’s hydrocarbon chain.  
The second CTAB’s ammonium group is positively charged and free to bind to HSA.  The 
hydrophobic pocket created in between the two CTAB molecules is free to bind drug.  Then, the 
amphiphilic properties of the HSA packing around the gold may have reinforced the PAC 
placement. 28  
To find the loading efficiency of the paclitaxel in the PAC-AuNR-HSAPs, the preparation 
procedure in Section 3.3.2 was followed with two distinct experimental changes: 1) the mass of 
HSA remained the same and the mass of PAC was varied and 2) the mass of HSA was varied 
and mg the mass of PAC remained constant. Figure 3.2a shows the results when 30 mg of HSA 
were prepared with either 0.1, 0.25 or 0.5 mg of PAC and the resulting PAC-AuNR-HSAPs 
were successfully loaded with 17 ± 2, 39 ± 5 and 92 ± 14 µg of PAC, respectively. The 
particles created with 0.5 mg PAC contained over 3 µg of drug per mg of HSA in finished 
particles. 
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Figure 3.2. (a) 30 mg of HSA was prepared with either 0.1, 0.25 or 0.5 mg of PAC: (solid line) 
µg of PAC loaded into the PAC-AuNR-HSAPs vs. the mg of PAC initially added to the 
preparation vial and (dashed line) the percentage of loaded PAC vs. PAC added to the 
preparation solution. (b) 0.5 mg PAC was added to particle preparation batches containing either 
20, 30 or 50 mg HSA (solid line) µg of PAC loaded into the PAC-AuNR-HSAPs vs. the mg of 
HSA present in the preparation vial and (dashed line) the percentage of loaded PAC vs. PAC 
added to the preparation solution when HSA is varied. 
 
Since the final particle suspension was in a volume of 1 mL, the resulting concentration of 
drug in the suspension was 133 µM. This concentration is the amount of drug entrapped within 
the batch of particles and can potentially be released to the tumor site via PPTT and temporally 
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during dynamic enzymatic activity in vivo. That loading concentration far exceeds the in vitro 
cytotoxicity of a paclitaxel-filled lipid emulsion in a previous study, which was shown to have 
a paclitaxel IC50 value of 5.5 µM on HeLa cells.97  The IC50 value is the half maximum 
inhibitory concentration, which is determined by a dose-response curve, and it indicates the 
concentration of drug that is required for 50% inhibition of the cancer cells in vitro.98 
Figure 3.2b shows results when 0.5 mg PAC was added to particle preparation batches 
containing either 20, 30 or 50 mg HSA. The resulting drug loading was 56 ± 14, 92 ± 14 and 
93 ± 20 µg PAC, respectively. There was a larger increase in drug loading when increasing 
mass of HSA in the sample from 20 to 30 mg HSA; followed by a plateu in PAC loading when 
using 30 or 50 mg HSA. The 30 mg HSA sample was still able to hold the most drug per mg of 
HSA: 3 µg PAC/mg HSA.  
The % PAC loading data shown in Figures 2a and 2b confirm the particles do not entrap 
more than roughly 17% of the 0.5 mg PAC added to the preparation solution, even when more 
HSA is available. This result was not fully understood, except for the hypothesis that the 
crosslinking of these particles might be playing a role in the effective drug entrapment as both 
the 30 mg and 50 mg particle batches were theoretically crosslinked at 40%. 
3.4.3 Effect of Crosslinking on Drug Loading  
The amine groups on the HSA are crosslinked by a condensation reaction with the aldehyde 
groups of glutaraldehyde.20  It has been calculated that the lowest required amount of 
glutaraldehyde needed to quantitatively crosslink all 59 ε-amino groups present in 100 mg of 
HSA is approximately 58.8 μL of  8% (V/V) glutaraldehyde (4.7 × 10-5 moles) in H2O. 20  All 
theoretical crosslinking calculations were based on this previous work and it has been customary 
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for groups working with this desolvation and crosslinking process to use percentage values to 
indicate the expected degree of crosslinking.85 
 
Figure 3.3. Average µg of PAC loaded into PAC-AuNR-HSAPs vs. the % of theoretical 
crosslinking of the particles. Error bars represent standard deviations of measurements (n > 3). 
 
To test whether the crosslinking played a major role in drug loading, two sample preparations 
of PAC-AuNR-HSAPs were created with 30 mg HSA and 0.5 mg PAC; one batch was 
theoretically crosslinked at 20% (2.87 × 10-6 moles glutaraldehyde) and the other at 40% (5.73 × 
10-6 moles glutaraldehyde).  As shown in Figure 3.3, the 40% crosslinked PAC-AuNR-HSAPs 
had more drug loading (92 ± 14 μg) with less deviation, while the 20% crosslinked particles had 
less consistent drug loading (53 ± 49 μg).  Although, some batches of the 20% crosslinked 
particles were capable of loading up to 102 μg of PAC, there was a large error associated with 
the loading.  Therefor crosslinking definitely plays a role in keeping the paclitaxel locked into 
the particles until it is provoked for release.  
3.4.4 PAC-AuNR-HSAP and AuNR-HSAP Heating Capabilities 
It has previously been discovered that when AuNR induced PPTT is used to create 
hyperthermia in human prostate tumor bearing mice, maintaining temperatures of 42-43˚C for 10 
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minutes showed an increase of macromolecular delivery into the tumor site. 99 In a separate 
study, when using paclitaxel-conjugated 11-mercaptoundecanoic acid-linked polyethylene glycol 
coated AuNRs, a combination of the drug and heating to 58˚C left absolutely no viable A549 
breast cancer cells. 28 Our approach allows for heating via selective temperature ranges, 
depending on the dosage of the PAC-AuNR-HSAPs delivered and the NIR treatment time.  
 
Figure 3.4.  Heating trend in ºC of (solid line) PAC-AuNR-HSAPs and (dashed line) PAC-
HSAPs 
 
A cell well-plate was placed under the vertically mounted laser and particle batches 
suspended in water and ethanol were placed in the wells.  The 808 nm laser was turned on at 2 W 
of power for up to 15 minutes while a thermocouple, placed on the side of the well, recorded the 
temperature continuously.  The particle solution was then collected via a pipette, centrifuged and 
the supernatant was saved for drug content analysis.  Figure 3.4 shows the heating trend (solid 
line) for PAC-AuNR-HSAPs created with 30 mg of HSA, 1.5 mL AuNR stock and 0.5 mg of 
PAC. The particles experience a sharp increase to 43ºC in roughly 5 minutes and continue to 46º 
within 15 minutes.  
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The dashed line in Figure 3.4 represents the heating ability PAC-HSAPs with no AuNRs 
inside; it is shown that these particles never reached a temperature over normal body 
temperature. The graph clearly shows that the AuNRs are necessary to cause substantial heating.  
Consequently, only cells with HASP-AuNR and exposure to laser radiation would experience 
hyperthermia. 
3.4.5 Drug Release via Photothermal Irradiation 
Literature reports state that paclitaxel has cytotoxic activity at concentrations as low as 50 
nM, and it was evident that the PAC-AuNR-HSAP delivery system was capable of loading far 
more paclitaxel than that (up to 133 μM in a 1 mL sample, shown in Section 3.4.2), while still 
maintaining heating abilities.100  The PAC-AuNR-HSAPs we created are true hybrids, where 
the anticancer functions of PPTT aided-uptake, heat ablation, EPR and drug release coexist, so 
it was important to know the heat-induced drug release.  Our method must prove drug release 
of at least the minimum cytotoxic dose via PPTT and temporal release in order to be a viable 
treatment vehicle 
In this study, the PAC-AuNR-HSAPs initially created with 0.1, 0.25 or 0.5 mg PAC (created 
with 30 mg HSA and crosslinked 40%) were irradiated with 808 nm NIR light for 15 minutes to 
monitor PAC release. These particles contained on average 56.1 ± 14, 91.8 ± 14 and 92.7 ± 20 
µg PAC and after only 15 minutes, they released 189 ± 108, 111 ± 33 and 124 ± 70 ng, 
respectively. In each case, a slight burst of release less than 1% of the loaded PAC was shown. 
Although a small percentage, the induced release would be considered an effective dose, with the 
lowest average concentration of 145 nM released into the 1 mL of irradiated solution. This is 
actually a desirable outcome, as a quick complete release of the drug payload can result in lower 
antitumor efficacy due to the subsequently quick drug clearance from the body.60  The ideal 
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antitumor treatment would be to harness the initial shock of the heat ablation and paclitaxel dose 
in a localized area, followed by the slower, continued release of the drug penetrating further into 
the tumor site via the leaky vasculature and heightened metabolism of the site. 
It is also worth noting that the particles which were created with different crosslinking 
percentages showed differences in drug release as well. The PAC-AuNR-HSAPs created with 
20% theoretical crosslinking released over 4% of the entrapped drug; an average of 932 ng 
PAC released vs. 124 ng (less than 1%) released by the 40% crosslinked particles. As found 
with the loading, there is a large statistical error for the drug release associated with the lesser 
crosslinked particles: 932 ± 646 ng.  The amount of drug that remains in the less tightly locked 
particles has a better chance of being released.  
Conversely, greater crosslinking allows for increased loading and the opportunity for 
prolonged release as well as decreased chances of drug release in areas other than the tumor 
site. These release results were compared to two control scenarios, where release was tested on 
irradiated PAC-HSAPs containing drug, but no AuNRs and on PAC-AuNR-HSAPs which 
were not irradiated. In both cases, the drug in the measured particle supernatant was below the 
detection limit of 0.00001 mg PAC/ mL using HPLC analysis. 
3.4.6 Temporal Drug Release  
Finally, to show that the paclitaxel was indeed released continually from the PAC-AuNR-
HSAPs after the initial irradiation period, three separate batches of PAC-AuNR-HSAPs 
samples (batches A, B and C) were created (each with 0.5 mg PAC and 40% crosslinking 
preparation parameters) and irradiated for 15 minutes. For each batch, the sample suspensions 
were centrifuged and the supernatants were removed for initial, laser provoked drug release 
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analysis.  Just as in Section 3.4.5, the initial burst of drug release for each sample batch was 
below 1% of the total loaded drug.   
The particle batches were then stored at 4 ºC for a certain amount of time: batch A was 
stored for 7 days, batch B for 14 days and batch C for 21 days in order to monitor subsequent 
drug release when no further irradiation is performed past the initial laser session. Figure 3.5 
shows the release trend for the post-irradiated particles. Total drug released after 7, 14, and 21 
days was 136 ± 22, 193 ± 36 and 224 ± 68 ng, respectively, for batches A, B and C.  For 
example, this means that after 7 days, samples in batch A experienced a further drug release of 
136 ± 22 ng in addition to the initial drug release the samples had already experienced during 
the irradiation session.  Therefore, Figure 3.5 is not a cumulative representation of drug release 
including the irradiation-provoked release, but rather it is a representation of how the PAC-
AuNR-HSAPs are capable of extended drug release post initial PPTT treatment. 
 
Figure 3.5. Average ng of unprovoked PAC released vs. Time in days. Error bars represent 
standard deviations of measurements (n > 3). 
 
100
150
200
250
300
350
0 7 14 21 28
AV
G.
 PA
C R
el
ea
se
d (
ng
)
DAYS
 56
This release was in water at a low temperature without irradiation, so it should be noted 
that the dynamic activity of a tumor at normal body temperature and a slightly acidic pH (as 
seen in tumor sites) will enhance the release rate. Even though PAC-HSAPs with no gold 
nanorods inside did not experience an initial irradiation-provoked burst of drug release because 
of their inability to sufficiently heat, the PAC-HSAPs did release 104 ± 22 ng over a 7 day 
period, compared to 136 ± 22 for PAC-AuNR-HSAPs. This confirms that any particles which 
do not end up with a gold nanorod inside will still complete the function of controlled drug 
release over time.   
What makes this even more promising is that PAC-HSAPs without AuNRs inside would 
travel alongside the PAC-AuNR-HSAPs in vivo and they may still experience the heating 
effects of the neighboring gold-filled particles. So, under biological conditions, the PAC-
HSAPs may still experience the initial burst of drug release during irradiation as well as 
undergo their temporal chemotherapeutic function. 
3.5 Conclusions 
In this study, hybrid PAC-AuNR-HSAPs were successfully prepared with simultaneously 
loaded drug and encapsulated AuNRs to show that these composite particles can serve as 
platforms for preparing new drug therapies.  The combined approach will allow killing of cancer 
cells by both hyperthermia and localized chemotherapy treatment and is more likely to eliminate 
all cancer cells.  The photothermal approach not only results in hyperthermic treatment, but it 
also serves as a trigger for drug release once the particles have reached their targeted tissue and 
may aid in controlled release only at the tumor site.  Functionalizing the surface of the HSAPs 
with disease-specific targeting ligands may lead to even more effective delivery of cancer 
 57
therapies to the site of the disease, boosting effectiveness and reducing damage to healthy 
tissue.42  
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Chapter 4  
Hybrid Gold Nanorod Human Serum Albumin Nanoparticles for 
Photothermal Therapy of Renal Cell Carcinoma 
 
4.1 Abstract 
In this study, the desolvation and crosslinking approach was employed to successfully 
encapsulate gold nanorods into HSAPs, forming AuNR-HSAPs (in accordance with Chapter 2) 
for in vitro studies. For particles created with the same amount of AuNRs, but varying amounts 
of HSA (1, 5 and 20 mg), the overall particle diameters were 409 ± 224, 294 ± 83 and 167 ± 4 
nm, respectively. It was found that particles created with more protein result in a smaller, but 
more controllable, desirable average diameter size. The particular AuNR-HSAPs in this chapter 
were synthesized for specific use in the plasmonic photothermal therapy (PPTT) of renal cell 
carcinoma (cell line 786-O), using 808 nm near-infrared laser irradiation.  Dosing experiments 
were done in vitro to determine the appropriate amount of unloaded-HSAPs and AuNR-HSAPs 
which can be delivered to the cells with limited inherent toxicity when no laser treatment was 
inflicted (dark treatments).   
Irradiation treatments were also completed to test the dosing amount of AuNR-HSAPs 
needed to facilitate sufficient temperatures for PPTT of the cancer cells. We found that even 
though an increase in the relative amount of HSA present during preparation leads to more 
unloaded-HSAPs present alongside the AuNR-HSAPs in the final particle suspension, it also 
leads to an increase in heating capabilities. An increase in HSAPs delivered also leads to more 
toxicity under dark treatment conditions. A dose of HSAPs/AuNR-HSAPs created with 20 mg 
versus 5 mg of HSA caused dark cell viability percentages of 64.5% and 87%, respectively. All 
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of the AuNR-HSAPs batches experienced photothermal heating of above 42 ˚C (sufficient for 
moderate hyperthermia) when delivered to the cells in a 1 mL dose (all particles created in a 
given batch).  After the full irradiation time, an MTT assay showed the AuNR-HSAPs PPTT 
effects: the strategy facilitated a significant decrease in cell viability to 0%.  
An imaging dye, coumarin-6, was used to visualize the cell uptake of the AuNR-HSAPs 
via fluorescence microscopy.  The particles did become fluorescently labeled and the cells 
showed signs of endocytosis when in contact with the AuNR-HSAPs. The system also lends 
itself to future customizable external functionalities such as stealth travel throughout the body 
and increased tumor uptake via conjugated targeting ligands. Internal entrapment of the 
chemotherapeutic medication sorafenib is currently being tested and optimized for tandem 
chemotherapeutic and photothermal therapies during a given treatment time. Animal models for 
in vivo testing are also being arranged in the near future for more dynamic treatment 
experiments. 
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4.2 Introduction 
Renal cell carcinoma (RCC) is the most common kidney-based malignant tumor and it 
does not respond to traditional chemotherapy and radiotherapy to the same extent as some other 
tumor types.96  The most used method of treatment has been partial nephrectomy, where the 
diseased portion of the kidney is removed. 92  This method is, of course, invasive and is 
especially dangerous for elderly and health-compromised patients. Diagnostic advancements of 
early-stage RCC have allowed for non-invasive treatments which spare much of the healthy 
kidney tissue. 99  
One such treatment is radiofrequency ablation, which uses a probe to inflict an alternating 
electrical current that induces heating of greater than 60˚C, with optimal temperatures between 
50-100˚C.99,101   If temperatures are too high (> 105˚C), the tissue can be charred; resulting in 
reduced dissemination and tissue resistance. Uncontrolled heating can also result in reduced 
renal function over time or uneven heating, nullifying the use of an alternative treatment. 
Therefore, tumor recurrences after heating are a problem, especially in larger tumors and 
radiofrequency ablation tends to require repeated ablations. 92, 101 
Despite the successes of thermal ablation on RCC, uncontrolled or incomplete heating, 
coupled with RCC’s increased drug resistance, calls for a better treatment method which delivers 
the best of both therapy options. Human serum albumin nanoparticles (HSAPs) filled with gold 
nanorods (AuNRs) form composite AuNR-HSAPs which offer a combative approach to solving 
both treatment problems. The AuNR-HSAPs can offer biocompatible, controlled heating in a 
specific location and the release of an increased dose of an otherwise dose-limiting 
chemotherapeutic drug. 
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In a previous study in Chapter 2, we focused on a proof-of-concept synthesis to fully 
encapsulate gold nanorods into size-controlled HSAP spheres with the future goal of taking 
advantage of the plasmonic photothermal therapy (PPTT) effects of the AuNRs without having 
them susceptible to clearing the body as fast as drug-conjugated AuNRs.41  The hybrid particles 
are drug-loading powerhouses capable of enhanced permeability and retention effects within a 
tumor site. 8, 9, 10    In Chapter 3, we reached the goal of successfully encapsulating the anticancer 
drug paclitaxel within the AuNR-HSAPs simultaneously with the AuNRs; with efficient loading.  
That research supplied evidence that the PAC-AuNR-HSAP hybrid delivery system offered 
simultaneous drug-release and PPTT as well as extended, controlled release of the drug over 
time.  
The work in this chapter aimed to prove that the AuNR-HSAP hybrid composites 
actually work to effectively kill cancer cells, without inherent toxicity, thus giving future purpose 
and promise to our former successes of being able to create and load drugs into the particles. 
Through fluorescence microscopy cell uptake studies and MTT cell assays, we show a definite 
increase in cell death with the use of the AuNR-HSAPs as a PPTT vessel. Current studies on 
loading AuNR-HSAPs with sorafenib, an angiogenesis inhibiting antitumor agent, are ongoing 
and hold much promise for a complete hybrid SRF-AuNR-HSAP in the near future for use in the 
RCC treatment of animal models. 60 
4.3 Experimental Methods 
4.3.1 Materials and Reagents 
Human serum albumin, lyophilized powder ≥ 97%, potassium bromide, Acrodisc® syringe 
filters with nylon membrane, diam. 13 mm, pore size 0.2 μm, Corning Costar cell culture plates, 
12 well, flat bottom and 8% aqueous glutaraldehyde were obtained from Sigma Aldrich (St. 
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Louis, MO). Ethanol, 200-proof, ACS/USP grade was obtained from Pharmco-AAPER (CT, 
USA). Water was distilled, deionized, and then further purified with a Barnstead Nanopure 
system.  The renal cell carcinoma cell line, RPMI media, coumarin-6, and materials for the MTT 
assay were supplied by Tulane University Medical Center. 
Bare gold nanorods (10 nm average axial diameter, 43 nm average length, surface plasmon 
resonance ~ 808-829 nm, OD = 1, 5.9 × 1011 AuNR/mL in water) were obtained from Nanopartz, 
Inc. (Loveland, CO). The AuNRs used were advertised by the vendor as “bare”, but they did 
contain trace amounts of cetyltrimethylammonium bromide.  
4.3.2 Synthesis of AuNR-HSAPs  
The AuNR-HSAPs were prepared using a conventional desolvation technique from 
Chapter 2 with the addition of AuNRs for seeding. 20, 81, 83  The standard method for 
preparation included creating an HSA stock solution of 100 mg HSA/ 1 mL of water.  After 
dissolving, the pH was around 7.  To an aliquot of the HSA stock solution (containing 1, 5 or 
20 mg of HSA), 2 mL (1.18 × 1012 AuNRs) of the AuNR stock solution was added, along with 
a small stir bar. Then, 100% ethanol was added to a known volume to denature the protein and 
facilitate aggregation. Upon addition of the ethanol, the solution became turbid.  Finally, an 
aliquot of 8% glutaraldehyde (aq.) was added to crosslink the AuNR-HSAPs. After 24 h of 
stirring, the particles were centrifuged at 13,000 rpm (16,060 g) for 20 minutes. The 
supernatant was removed and the remaining particle pellet was washed twice by resuspending 
AuNR-HSAPs in water via ultrasonication. The final particles were redispersed and stored at 4 
°C in water. The final particle suspensions were named by the amount of HSA in mg used in 
the preparation process: 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20-AuNR-HSAPs for 1, 5, and 
20 mg HSA, respectively. 
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4.3.3 Dynamic Light Scattering 
The completed HSAPs were characterized by measuring the diameter, mobility, and zeta 
potential using a Mobius dynamic light scattering (DLS) instrument (Wyatt Technology 
Corporation, Santa Barbara, CA).  Samples were diluted with water prior to analysis. 
4.3.4 SEM and TEM 
Particles were imaged using a field emission-scanning electron microscope FESEM, LEO 
1530VP (LEO Elektronenmikroskopie GmbH, Oberkochen, Germany). HSAPs were sputtered 
with a thin film of gold or silver to facilitate imaging. Transmission electron microscope (TEM) 
images were acquired with a JEOL Model 2010 TEM. 
4.3.5 Cell Line 
 RCC 786-O were incubated in 30, 1cm diameter wells. They were grown to approximately 70-
80% confluence in 1mL of RPMI media at a temperature of 37° Celsius and at 5.0% CO2, using 
Forma ScientificTM CO2 Water Jacketed Incubator Model 3110 (115V, 3.6A, 50/60Hz). 
4.3.6 Laser Irradiation of Particles 
The final, washed AuNR-HSAPs and HSAPs were tested for heating ability and cell death 
via laser irradiation. To heat the samples, an aliquot of the particle sample was placed into a well 
of a 28-well plate containing renal cell carcinoma. The plate was placed approximately 4 to 6 
inches under a vertically mounted laser. A LabSpec 808 nm collimated diode laser system was 
used at a continuous wave power output of 2000mW for 30 minutes (irradiated) or zero minutes  
(dark)for each sample. The size of the beam was approximately 1 × 1 cm. Temperature changes 
caused by the irradiation sessions were measured using a Spark Science Learning System™ 
model PS-2008A thermocouple.  
 64
The cells received a total of 1 mL of liquid: an aliquot of media and a dose of the Au-
HSAP suspension (50 µL, 0.5 mL or 1.0 mL) that contained either a control condition 
containing no particles, unloaded-HSAPs, bare AuNRs or 1-, 5- or 20-AuNR-HSAPs.  Every 
batch of AuNR-HSAPs contained some HSAPs that formed with no gold nanorods within 
them; therefore there is always a certain ratio of unloaded-HSAPs to AuNR-HSAPs in a batch. 
For the preparation methods 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20-AuNR-HSAPs (all 
with 1.18 × 1012 AuNRs), the resulting finished particle batches contained varying ratios of 
unloaded-HSAPs and AuNR-HSAPs. All samples were kept out of the incubator for the same 
amount of time to ensure that no cells were protected from the effects of the environment any 
more than cells currently being irradiated.  After irradiation, the contents of the wells were 
assayed via an MTT assay for cell viability testing.  
4.3.6 MTT Assay 
 Cell viability after AuNR-HSAPs and HSAPs treatment was measured by MTT assay. The 
assay used a tetrazolium compound (Sigma Aldrich, St. Louis, MO), which when reduced by 
intracellular mitochondrial dehydrogenase enzyme, converts tetrazolium into purple formazan 
indicating the magnitude of cell viability. The viability of cells post treatment was measured by 
the quantification of purple formazan by colorimetric method using a spectrophotometer 
(Beckman Coulter, Inc., Schaumburg, IL). 
4.3.7 Cell Uptake Studies via Fluorescence Microscopy 
RCC 786-O were incubated in 3 separate plates of 10mL of RPMI media at a temperature of 
37° Celsius and at 5.0% CO2. An aliquot of 0.5 mL of unloaded-HSAPs, coumarin-6 loaded 
AuNR-HSAPs was added and incubated for 24 hours before images were taken using an 
Olympus IX70-S1F2 fluorescence microscope (220-240V, 1.8/0.8A, 50/60Hz) with an Olympus 
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DP71 camera (12.5 megapixel) and Olympus BH2 RFL- T3 Power Supply (100-120V, ~2.8 A, 
50-60Hz). 
4.4 Results and Discussion 
4.4.1 Formation of AuNR-HSAPs 
Using the desolvation and crosslinking process discussed in Chapter 2 to create thiol 
bonds between the AuNRs and the HSAPs, a self-assembly process facilitated the formation of 
a spherical HSAPs (see Table 4.1) around the AuNRs with average particle size diameters of 
409 ± 224, 294 ± 83 and 167 ± 4 nm when using 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20-
AuNR-HSAPs, respectively. 14  The zeta potential values for those AuNR-HSAPs were -39 ± 
3, -35± 4 and -33 ± 3 mV, respectively.   It is evident from the size information that as the 
mass of HSA increased, the average particle size became smaller, with less deviation. Since the 
zeta potential values for these size distributions reflect stable particles, we are confident that 
these fluctuations are actually large distributions in size and not reflections of sizable 
aggregates. 
When using 1-HSAPs, 5-HSAPs and 20-HSAPs without gold nanorods (see Table 4.1), 
unloaded-HSAPs were created with average diameters of 400 ± 160, 182 ± 46 and 174 ± 3 nm, 
respectively. The zeta potential values for the particles were -26 ± 8, -22 ± 8 and -35 ± 3 mV, 
respectively. This size and zeta potential information for unloaded-HSAPs depict a trend of 
smaller particle sizes for a given amount of protein when no Au rods are present, with the 
exception of the particles created via 20-HSAPs. The deviations in size also decreased. The 
zeta potential values continued to reflect stability of the particles, however the AuNR-HSAPs 
showed greater stability than the unloaded-HSAPs.  This stability increase was a desirable 
result; as it reflects another benefit of the hybrid particle. 
 66
 
Table 4.1. Particle sizes and zeta potential data for AuNP-HSAPs and Unloaded-HSAPs used on 
RCC. 
 AuNR-HSAPs Unloaded-HSAPs 
mg HSA in 
Preparation Method 
Avg. Diameter 
(nm) 
Zeta Potential 
(mV) 
Avg. Diameter 
(nm) 
Zeta Potential 
(mV) 
1 409 ± 224  -39 ± 3  400 ± 160 -26 ± 8  
5 294 ± 83 -35 ± 4 182 ± 46 -22 ± 8 
20 167 ± 4 -33 ± 3 174 ± 3 -35 ± 3 
aError represents one standard deviation with N ≥ 3.  
 
When comparing this data to the initial size values obtained for AuNR-HSAPs in Chapter 2, 
there are some size difference due to differences in crosslinking, ethanol volumes, mass of HSA 
used and volume of stock AuNR solution used. 
4.4.2 Unloaded-HSAP and AuNR-HSAP Dark Effects on Renal Cell Carcinoma 
Upon dispersion of a prepared sample into water, the final volume was 1 mL of suspension. 
In an attempt to find any inherent toxicity caused by the particles, dark experiments were 
performed on the RCC using either 50 µL, 0.5 ml or 1.0 mL doses of the finished particle 
batches. Table 4.2 displays the viability data for the ‘dark’ treatment for both Unloaded-HSAPs 
and AuNR-HSAPs created with varying amounts of HSA. There is a definite correlation between 
the number of particles placed onto the cells and cell death.  
For the Unloaded-HSAPs, it is theorized that 20-HSAPs creates far more particles due to the 
increase in protein available for particle formation, thus the cells may become overwhelmed by 
the 1.0 mL full batch dose and the cell viability is only 13%.  However, when the 20-HSAP 
prepared particles were dosed with only 0.2 or 0.05 mL of the originally prepared 1 mL particle 
suspension, the cell viability was 70 and 80%, respectively. This viability increase proves that it 
is not the 20-HSAPs themselves that are toxic to the RCC, but it is the amount of particles 
delivered which causes some toxicity.  
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 The 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20-AuNR-HSAPs also caused a decrease 
in cell viability with a 0.5 mL dose, with the 5-AuNR-HSAPs causing the least amount of cell 
death at 87%.  It is interesting that the viability does not change much from the 50 µL dose 
when using the 5-AuNR-HSAPs preparation type. It is clear that using the entire batch of 
particles, a 1.0 mL dose, is too much for the RCC to handle and nearly all cells are killed 
without irradiation. 
Table 4.2. ‘Dark’ Treatment: Cell Viability Data for RCC Dosed with 0.05, 0.5 or 1.0 mL of 
Unloaded-HSAPs or AuNR-HSAPs of Varying HSA Amounts 
% Cell Viability After ‘Dark’ Treatment 
mg HSA in Sample 
Preparation 
Amount of Unloaded-HSAPs or AuNR-HSAPs Sample 
Added to the RCC 
 50 µL  0.5 mL 1 mL  
0 (Control) 100% 100% 100% 
    
5-HSAPs 94% - - 
20-HSAPs - - 13% 
    
1-AuNR-HSAPs 86% 53% 0.6% 
5-AuNR-HSAPs 84% 87% 2.9% 
20-AuNR-HSAPs - 65% 4.5% 
Hash mark indicates no data available for a particular study. 
4.4.3 Photothermal Irradiation Effects on Renal Cell Carcinoma 
Understanding that the dose should be 0.5 mL or lower for a particular preparation method, 
irradiation studies were still done with 50 µL, 0.5 mL and 1.0 mL doses.  Initially, when 50 µL 
of 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20-AuNR-HSAPs were added to the cell wells, none 
of the trials were able to decrease cell viabilities to below 37% or final temperatures above 44°C 
when irradiated for 30 minutes. While that temperature may cause moderate hyperthermia, 
temperatures above 46°C are needed to induce coagulative necrosis. 45, 93  It became evident that 
the number of AuNRs had to be increased in order to reach sufficient heating, therefore the 
number of AuNR-HSAPs had to be increased. 
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An interesting trend as seen in Figure 4.1 was, despite the samples having equal amounts of 
AuNRs present within the particles, the 20-AuNR-HSAPs samples were able to heat the cells to 
the highest temperature. The reason for this phenomena is not exactly known, however it is 
speculated that the HSAP acts as some sort of spacer for the rods, thus allowing them to be more 
individually effected by the light. One study found that increased amount of AuNRs past 0.5 nM 
has an adverse effect on heating because of increased light absorption and decreased 
photothermal conversion. 45  When delivered in a 1.0 mL dose, the 20-AuNR-HSAPs 
experienced heating up to 51˚C after only 5 minutes a temperature necessary to cause severe 
cellular hyperthermia and necrosis.   
 
 
Figure 4.1. Heating Capabilities of AuNR-HSAP batches made with varying mg HSA and 
heated in either 0.5 or 1.0 mL doses. 
 
Table 4.3 displays the cell viability information for the irradiated cells treated with particles.  
Minimal warming was experienced when the laser was directed at RCC that were not treated 
with particles (control). The Unloaded-HSAPs also experienced minimal warming, with cell 
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viability dropping to 92% for the irradiated study from 94% during the dark study. The 1.0 mL 
dose of particles had already experienced almost complete cell death during the dark study, so 
the increase in necrosis after irradiation was not surprising. 
The true testament to the effectiveness of the irradiation on the AuNR-HSAPs was the 0.5 
mL dose of all three sample preparation types. The 1-AuNR-HSAPs, 5-AuNR-HSAPs and 20-
AuNR-HSAPs all experienced decreases in the percentage of viable cells, as seen in Figure 4.2.  
 
Table 4.3. 'Irradiated’ Treatment: Cell Viability Data for RCC Dosed with 0.05, 0.5 or 1.0 mL of 
Unloaded-HSAPs or AuNR-HSAPs of Varying HSA Amounts 
% Cell Viability After ‘Irradiated’ Treatment 
mg HSA in Sample 
Preparation 
Amount of Unloaded-HSAPs or AuNR-HSAPs Sample 
Added to the RCC 
 50 µL 0.5 mL  1 mL  
0 (Control) 99.5% 99.5% 99.5% 
    
5-HSAPs 92% - - 
    
1-AuNR-HSAPs 86% 36% 0.2% 
5-AuNR-HSAPs 68% 25% 1.6% 
20-AuNR-HSAPs - 3.6 0% 
Hash mark indicates no data available for a particular study. 
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Figure 4.2. Percent viability of Renal Cell Carcinoma after 'dark' (red bars) or 'irradiated' (blue 
bars) treatment using AuNR-HSAPs made with varying mg HSA: 1, 5 or 20 mg. 
 
It is worth noting that bare AuNRs killed of over 35% of the cancer cells without irradiation. 
Even though the nanorods are marketed as “bare”, with almost all CTAB washed off, there are 
still some residual amounts which has been shown to exhibit cytotoxicity unless properly 
encapsulated.80  A proof of concept trial using only the bare AuNRs reached 59.7C with 100% 
cell kill.  AuNRs produced both the highest temperatures and the highest rate of cell kill, but also 
demonstrated cytotoxicity in the absence of irradiation, whereas 1-AuNR-HSAPs showed less 
cell kill but also demonstrated less cytotoxicity. HSAPs alone and 1-AuNR-HSAPs did not 
produce cell kill rates higher than 15%.  Low doses (0.5 mL or less) of 20-AuNR-HSAPs seem 
the best therapeutic option moving forward.  
4.4.4 Fluorescence Cell Uptake Studies 
In order to determine whether the HSAPs were indeed being taken into the RCCs, a 
fluorescence uptake study was performed using coumarin-6 dye as a label.  Particles created via 
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5-AuNR-HSAP were prepared in the presence of the dye.  Figure 4.3 shows the fluorescence 
microscopy of the coumarin-6 labeled AuNR-HSAPs after incubation with the renal cell 
carcinoma.  The particles are underwent endocytosis but were taken up into the cell nucleus. 
Coupled with the irradiation data, these results are promising and display sufficient evidence that 
the AuNR-HSAPs will be in close enough proximity to diseased cells to cause necessary 
temperature increases upon irradiation in vivo.  
 
Figure 4.3. (a) Confocal Microscope image of Renal Cell Carcinoma Treated with coumarin-6 
labeled AuNR-HSAP-5 and (b) the fluorescence emission of the same cells. 
 
4.5 Conclusions 
In this study, hybrid AuNR-HSAPs were successfully prepared and showed more 
controllable size distributions when more protein is added to the preparation vial. The particles 
were able to heat to necessary temperatures in order to cause renal cell carcinoma death, but 
careful consideration of the particle dose has to be maintained in order to not overwhelm the 
cells without irradiation.  This incidence of dark condition cell death may not matter very much 
in a tumor site, however necrosis of healthy cells surrounding the tumor site must be avoided 
during the time it takes for all of the AuNR-HSAPs to become trapped in the tumor vasculature.    
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Since, fluorescence microscopy showed that the cells were taking up the AuNR-HSAPS, 
functionalizing the surface of the HSAPs with disease-specific targeting ligands may lead to 
even more effective delivery of cancer therapies to the site of the disease, boosting effectiveness 
and reducing damage to healthy tissue. 42 
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Chapter 5 
Loading CPT (camptothecin) and BACPT (7-butyl-10-aminocamptothecin) 
Into Human Serum Albumin Nanoparticles for use as a Targeted Therapy 
Platform  
 
5.1 Abstract 
Camptothecin, a natural antineoplastic agent, and BACPT (7-butyl-10-
aminocamptothecin), an analogue of camptothecin (CPT), have garnered attention in the medical 
field due to their high effectiveness against pancreatic, lung and ovarian cancers, however due to 
their water insolubility, they has been lacking in fulfilling their potential as major anti-cancer 
pharmaceuticals unless they have been manipulated in some way. Manipulations such as creation 
of a prodrug or attachment of solubility ligands cause a decrease in the effectiveness of the drugs 
and there is still a problem of toxicity. Camptothecin and BACPT also possess a propensity to 
open their lactone rings in the presence of water forming a carboxylated version of the drug, 
which some research suggests, causes some loss in effectiveness. Carboxylated camptothecins 
also possess a high binding affinity for HSA, so are susceptible to being carried away from the 
tumor site prematurely by molecular HSA, causing reduced efficacy.   
However, there is evidence that, when in high enough concentrations, the carboxylate 
form of camptothecins have the ability to effectively kill or slow the growth of cancer cells as 
well as the lactone form.  By taking advantage of the CPT’s and BACPT’s affinities to HSA and 
entrapping the BACPT within human serum albumin nanoparticles (HSAPs), which have had 
success as a colloidal carrier system for targeted treatment of cancer, the amount of drug that 
reaches the cancer site can be greatly enhanced. This enhancement can potentially increase 
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efficacy, safety and treatment success. HPLC and fluorescence spectroscopy were used to 
determine drug loading efficiency.   
Both the CPT-HSAPs and the BACPT-HSAPs showed toxicity to human sarcoma cells in 
vitro. However, finding the drug loading amounts that caused the desirable toxicity was a 
challenge. HPLC proved unreliable as an analytical technique for CPT and BACPT due to 
inconsistent results from lactone conversion during the mobile phase. CPT could not be 
determined via fluorescence spectroscopy as well due to sporadic, uncontrollable changes in the 
fluorescence emission.  The loading of BACPT into BACPT-HSAPs was determined via HPLC 
and fluorescence spectroscopy and compared. 
This research reports an efficient strategy for preparing 200-300 nm, size-controlled 
BACPT-HSAPs with up to 5.25 micrograms of BACPT/ mg of HSA, as determined by 
fluorescence spectroscopy. The BACPT-HSAPs showed evidence of cell necrosis for human 
sarcoma cancer cells during in vitro studies. This proof of concept research shows that BACPT-
HSAPs are effective at killing cancer cells when the BACPT is present in both carboxylate and 
lactone forms. The strategy also enables maximum external surface area for future 
functionalization of targeting ligands for stealth-like disease detection. 
5.2 Introduction 
Camptothecins are used on primary and metastatic colon carcinoma, platinum-refractory 
ovarian cancer, and small cell lung carcinoma.  It acts by poisoning the DNA target enzyme 
topoisomerase I (top I) during its catalytic cycle of DNA relaxation, leading to the generation of 
DNA double-strand breaks and cell death by apoptosis.46,48,49,50 BACPT, 7-butyl-10-
aminocamptothecin (Figure 5.1), was developed in an effort to improve potency and cross-
resistance profiles of camptothecins.54   BACPT is promising because it has been found that a 
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substitution at the C-10 position (See Figure 5.1) increases lipophilicity while substitution at the 
C-7 position enhances potency in vitro. When binding to DNA, BACPT intercalates at the site of 
DNA cleavage and is stabilized by an E-ring hydrogen bond contact with an aspartic acid. 54,55  
The A-ring’s amine at the C-10 position also forms a hydrogen bond to an oxygen atom of the 
side chain of a glutamine moiety. The C7- butyl moiety causes a very good steric fit of BACPT 
with the top I enzyme, and the planar ring system of the drug mimics a DNA base-pair.54,55 
 These effects correlate with increasing persistence of the DNA cleavage complex created 
by BACPT.54,55  Hiding the highly effective BACPT and CPT in a biocompatible protein sheild 
in concentrations high enough to overcome the  effects of the reduced lactone version will 
accomplish the task of maximizing efficiency while minimizing harmful effects. 
 
Figure 5.1. BACPT 
 
There has been some debate as to whether the antitumor activity is fully lost when a 
camptothecins undergo a transforation to the carboxylate verion after they come into contact 
with physiological pH and the structure of a blood protein such as HSA or if the process is 
indeed a reversible process (Figure 5.2). 102  However, studies have shown evidence to suggest 
that a significant amount (33% at pH 7.4, 66% at pH 6.8) of uncharged carboxylated BACPT 
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could enter tumor cells at acidic pH and accumulate in mitochondria to inhibit mitochondrial top 
I. 58  This is compared to the lactone form where 83-100% of the BACPT remains uncharged. 58  
It has also been demonstrated that the carboxylate version of camptothecin sodium has been 
effective against L1210 leukemia and carboxylate topotecan can bind to top I. 103, 104   A recent 
study proved that the inhibitory rate of tumor percent caused by 9-nitrocamptothecin was 
significant down to 25% lactone (vs. carboxylate) in tumor bearing mice. 105  The pH sensitive 
antitumor drug is desirable because it can exploit the pH gradient which exists in solid tumors 
but not in normal tissues 106.   
 
Figure 5.2. Structure of CPT at physiological versus acidic pH. 
 
The innovation of this project is the strategic use of HSAP’s enhanced permeation and 
retention effects to entrap the aggressive, insoluble CPT and BACPT for more concentrated 
release at a tumor site; increasing the dosage safely. The CPT/BACPT must be in continuous 
contact with replicating cancer cells to be optimally therapeutic, therefore keeping the drug in 
constant release, even in carboxylate form, in the acidic tumor is desirable. 105, 107  In this study, a 
desolvation and crosslinking entrapment method facilitated size-controlled HSAP shells for 
efficient internal enclosure of BACPT and CPT, as well as maximum external surface area for 
future functionalizing of targeting ligands for disease detection. We have used an in vitro human 
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sarcoma cell culture as a preliminary study of the effectiveness of BACPT-HSAPs for cancer 
treatment. 108 
5.3 Experimental Methods 
5.3.1 Materials and Reagents 
Human serum albumin, lyophilized powder ≥ 97%,  8% aqueous glutaraldehyde, RPMI 
1640,  porcine trypsin - 1X Solution,  fetal bovine serum, streptomycin and amphotericin, were 
obtained from Sigma Aldrich (St. Louis, MO).  Ethanol, 200-proof, ACS/USP grade was 
obtained from Pharmco-AAPER (CT, USA), Phosphate buffer (pH 7.2) and a Mini-Pump 
Variable Flow peristaltic pump were obtained from VWR International (Radnor, PA). An 
AccuSpin Micro centrifuge was obtained from Fisher Scientific (Pittsburg, PA).  Water was 
distilled, deionized, and then further purified with a Barnstead Nanopure system. Camptothecin 
(S) (+) was obtained from VWR and BACPT was obtained from Dekk-Tec, Inc. (New Orleans, 
LA). Cells: “CL” Human Sarcoma, cultured from a patient; Brain Dekk-Tec. Inc., 725 Topaz St, 
New Orleans, LA) 
5.3.2 Synthesis of Unloaded HSAPs 
The HSAPs were prepared using a conventional desolvation technique.6, 15, 82, 81, 83   The 
standard method for preparation included addition of 20 mg of solid HSA to 1 mL of water . 
After dissolving, the pH was around 7.  A small stir bar was added to the solution, and 3 mL of 
100% ethanol was added at a rate of 1 mL/min using a peristaltic pump.  Upon addition of the 
ethanol, the solution became turbid. Finally, 4.7 μL of 8% glutaraldehyde (aq.) was added to 
crosslink the HSA within the particles.  After 24 h of stirring at room temperature, the particles 
were centrifuged at 13,000 rpm (16,060 g) for 30 minutes to 1 hour. The supernatant was 
removed and the remaining pellet was ultrasonicated and resuspended. The suspension was 
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washed twice with water with intervening centrifugation steps. The washed particles were 
ultrasonicated in water and stored at 4 °C.  
5.3.3 Synthesis of BACPT-HSAPs   
The procedure for preparing the drug-loaded particles followed section 5.3.2 with a 
modification to the ethanol addition step and final volume. To create the BACPT loaded 
HSAPs, a stock solution of the BACPT was first created: 1 mg BACPT/mL ethanol. Then, an 
aliquot of the drug stock solution was added to more ethanol. The BACPT/EtOH solution was 
added to an HSA sample solution drop-wise. The overall parameters used for preparing HSAPs 
loaded with varying amounts of BACPT are provided in Table 5.1 (all samples contained 4.7 
µL of 8% glutaraldehyde; causing 40% theoretical crosslinking). The washes for the drug-
loaded particles were done with a solution of 1:3 water:ethanol.  
Table 5.1. Preparation Parameters for all BACPT-loaded HSAPs 
Sample 
Preparation Type 
Drug Stock 
Solution (mL) 
EtOH 
(~mL) 
Drug Added 
(mg) 
BACPT-HSAP-1 0.01 3.99 0.01 
BACPT-HSAP-2 0.1 3.9 0.1 
BACPT-HSAP-3 0.25 3.75 0.25 
BACPT-HSAP-4 0.5 3.5 0.5 
BACPT-HSAP-5 1 3.0 1 
 
5.3.4 Synthesis of CPT-HSAPs   
The procedure for preparing the drug-loaded particles followed section 5.3.2 with a 
modification to the ethanol addition step and final volume. To create the CPT loaded HSAPs, a 
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stock solution of the CPT was first created: 1 mg CPT/mL in 2:3 chloroform:ethanol. Then, an 
aliquot of the drug stock solution was added to more ethanol. The CPT/EtOH solution was 
added to an HSA sample solution drop-wise. The overall parameters used for preparing HSAPs 
loaded with varying amounts of CPT are provided in Table 5.2 (all samples contained 4.7 µL 
of 8% glutaraldehyde; causing 40% theoretical crosslinking). The washes for the drug-loaded 
particles were done with a solution of 1:3 water:ethanol.  
Table 5.2. Preparation Parameters for all CPT-loaded HSAPs 
Sample 
Preparation Type 
Drug Stock 
Solution (mL) 
EtOH 
(~mL) 
Drug Added 
(mg) 
CPT-HSAP-1 0.1 3.9 0.1 
CPT-HSAP-2 0.25 3.75 0.25 
CPT-HSAP-3 0.5 3.5 0.5 
 
5.3.5 Absorbance 
Absorbance measurements of the BACPT-HSAPs were performed with a Cary 60 
absorbance spectrometer (Agilent Technologies). 
5.3.6 HPLC 
The HPLC system used was an Agilent 1100 instrument (Palo Alto, CA) with a diode array 
absorbance detector.  The column was an Agilent Eclipse XDB-C18 column (150 X 4.6 mm, 
particle size 5μm). The injection volume was 200 μL, and the absorbance wavelength used for 
quantitation of BACPT was 227 nm and for CPT it was 254 nm. The mobile phase was 60% 
acetonitrile: 40% water at a flow rate of 1 mL/minute.  
  
 80
5.3.7 Fluorescence 
Fluorescence was measured with a Cary Eclipse fluorometer with excitation for BACPT at 
403 nm and emission scanned from 413-600 nm.  For CPT, the excitation wavelength was 358 
nm and the emission was scanned from 368-550 nm.  Excitation and emission slits were 2.5 nm.  
5.3.8 Dynamic Light Scattering 
The completed HSAPs were characterized by measuring the diameter, mobility, and zeta 
potential using a Mobius dynamic light scattering (DLS) instrument (Wyatt Technology 
Corporation, Santa Barbara, CA).  Samples were diluted with water prior to analysis. 
5.3.9 Microscopy 
Particles were imaged using a field emission-scanning electron microscope FESEM, LEO 
1530VP (LEO Elektronenmikroskopie GmbH, Oberkochen, Germany). HSAPs were sputtered 
with a thin film of gold or silver to facilitate imaging.  To check cell vitality after the addition of 
nanoparticles to the cancer cells, a compound microscope was used; Meiji Techno, TC5300, 
Compound - 100x on large view, 200x in zoom view, (Meiji Techno America, San Jose, CA) 
5.3.10 Cell Cultures  
Cell vitality studies were performed by two different methods.  
CELL METHOD 1. For visual cytotoxicity studies without washing off unloaded-HSAPs, 
CPT-HSAPs or BACPT-HSAPs: On a 12-well cell plate, to the each well, 1 mL of sterile RPMI 
media was added, then, 1-drop aliquots of diluted (with RPMI) or undiluted harvested cell 
solutions were placed into every well. The well plates were incubated at 37°C for 24 hours to 
facilitate cell growth.  After the 24 hour period, addition of the nanoparticles was accomplished 
by adding 0.5 ml of the particle solution being tested; either unloaded-HSAPs or a particular 
concentration of CPT-HSAPs or BACPT-HSAPs. The control was a well containing only cells 
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and no nanoparticles. After the plates were incubated again with the particles at 37°C for 24 
hours, the cells were visually checked for blebbing and necrosis on the compound microscope; 
with the nanoparticles still present. 
CELL METHOD 2. For visual cytotoxicity studies involving field of view differences after 
washing the wells of nanoparticles and dead cells: the well plates were prepared as they were in 
cell method 1, but after the initial incubation period, only 0.1 mL of particle solution being tested 
was added. A control of cells only was prepared a well. After 24 hours of incubation, the wells 
were removed of all particles and dead cells by pipetting off all media in which they were 
incubated. The wells were washed twice with 1 mL of fresh RPMI. Any remaining cells were 
viable and stuck to the well plate. Dead cells were washed away. A visual inspection on the 
compound microscope showed differences in the live cell population of the control and the 
treated wells.     
5.4 Results and Discussion 
5.4.1 Formation and Characterization of BACPT-HSANPs  
The same thermodynamically driven self-assembly process for polymeric materials was used 
in this chapter and proceeded by the addition of a denaturing agent to denature HSA in the 
aqueous phase, causing aggregation, thus facilitating electrostatic and hydrophobic 
interactions.14,18  
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Figure 5.3. FESEM images of BACPT-HSANPs. 
 
This process yielded samples with a size of 248 ± 66 nm, therefore it was assumed that the 
BACPT-HSAPs created under similar desolvation parameters would yield roughly the same 
particle size. That hypothesis proved correct. All five BACPT-HSAP preparation methods 
yielded average size measurements within 227 ± 19 and 247 ± 30 nm.  Figure 5.3 is an FESEM 
image of BACPT-HSAPs showing that particles created in the presence of BACPT do not lose 
their characteristic spherical shape or size. These BACPT-HSAPs created were still in a proven 
effective size range for use as a targeted treatment vehicle. 
BACPT-HSAPs created were still in a proven effective size range for use as a targeted 
treatment vehicle.  
Table 5.3. Preparation Type vs. Overall size of Completed BACPT-HSAPs 
Sample Preparation Type Drug Added (mg) Average BACPT-HSAP Size (nm) 
BACPT-HSAP-1 0.01 234 ± 42 
BACPT-HSAP-2 0.1 235 ± 20 
BACPT-HSAP-3 0.25 242 ± 5 
BACPT-HSAP-4 0.5 227 ± 19 
BACPT-HSAP-5 1 247 ± 30 
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The overall average particle sizes for loading scenarios 1 thru 5 do not vary drastically, as 
seen in Table 5.3. This research focuses on entrapping the BACPT described above into a shell 
of HSAP big enough to also bind and hold an extremely high, maximum payload of drug while 
succumbing to the EPR effects that will cause it to be trapped in a cancerous matrix, so the 
consistent particle size is desirable.  
5.4.2 Determination of Loading Efficiency of BACPT via HPLC 
It was a concern that using HPLC as a quantitation method would not be an accurate 
representation of the amount of drug washed off of the particles because the HPLC mobile phase 
contains water. As discussed previously, water (at neutral pH) has the ability to open the 
BACPT’s lactone ring (as seen in Figure 5.3), thus causing the structure of the BACPT to 
change, potentially resulting in a shift of the characteristic peak.  Figure 5.4 shows absorbance 
spectra of 0.5 mg/mL solutions of a BACPT. The dashed line represents the absorbance of a 
solution of BACPT in 1:4 water: ethanol; consistent with the solvent matrix in the particle 
preparation supernatant. The solid line represents the absorbance of BACPT in 50:50 water: 
ethanol; consistent with a “wash”. It is clear that there is absorbance spectrum shift with the 
addition of more water in the BACPT matrix. This could affect the HPLC results, along with the 
conformational change in the BACPT molecule which is responsible for the shift. 
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Figure 5.4. Absorbance spectra of (solid line) 0.5 mg/mL BACPT in 50:50 water:ethanol and 
(dashed line) 0.5 mg/mL BACPT in 1:4 water:ethanol. 
 
 Despite the shift, we sought to find out if HPLC could achieve drug quantitation in the 
initial supernatant and subsequent particle washes. HPLC analysis of the particle preparation 
supernatant and wash solutions were compared to a set of drug solution standards in 1:3 
water:ethanol to mimic the matrix of the preparation solution. Figure 5.5 shows an HPLC 
spectrum for a sample created with the BACPT-HSAP-4 preparation parameters (0.5 mg of 
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BACPT added) and revealing a BACPT peak at 5.3 minutes.  
 
Figure 5.5. HPLC spectrum of the initial centrifugal supernatant from a sample created with 0.5 
mg BACPT. The BACPT manifests a peak at 5.3 minutes. 
 
As discussed previously, water and its neutral pH has the ability to open the BACPT’s 
lactone ring, thus causing the structure of the BACPT to change, potentially resulting in a shift of 
the characteristic peak. It was indeed noted that the longer the samples (and standards) were 
allowed to sit (even refrigerated), there was a reduction of the ~ 5 minute peak area. When 
samples were compared to older standards, there was an undesirable finding of the calculated 
drug washed off of the particles being higher than the amount of drug actually added to the 
sample during preparation.  
Given the impossibility of this result being accurate, all samples had to be analyzed within 48 
hours of preparation and again, the washes could not be done with water alone but with an 
ethanol mixture. Upon HPLC analysis of BACPT-HSAPs prepared by either, BACPT-HSAP-1, 
BACPT-HSAP-4 or BACPT-HSAP-5, there was an increase in drug loading.  
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Figure 5.6. Relationship of starting mg BACPT added to a particle batch compared to the mg 
BACPT trapped within the particles in that batch.  The measurements shown are the average 
calculated values of drug trapped for the preparation types BACPT-HSAP-1, BACPT-HSAP-4 
and BACPT-HSAP-5. 
 
Figure 5.6 shows the relationship created by comparing the mg of BACPT added to the initial 
formation solution and the calculated mg of BACPT trapped within the HSAPs, as determined 
via HPLC. The average loading of BACPT into HSAPs when 0.01, 0.5 and 1.0 mg of BACPT 
was added to a preparation solution was 3.8, 112.1 and 281.8 mg BACPT, respectively.  This is a 
final average drug concentration range of 3.8 to 281.8 µg/mL if the particles are resuspended in 1 
mL of water. The particle solutions had resulting BACPT concentrations ranging 9.1 to 671 nM.  
In each batch, the amount of HSA remained unchanged at 20 mg, therefore, there is clear 
evidence that the HSAPs can hold an increasing amount of BACPT, but never all of the BACPT 
added. There is a loading factor taking place here that is not clearly known. What is clear 
however, is that further increasing the amount of BACPT into the preparation solution should 
continue to increase the amount of BACPT capable of being trapped within 20 mg of HSAP until 
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a plateau is reached at max loading capacity. In an effort to spare resources, we did not 
investigate this loading maximum, as it has been shown that BACPT concentrations in the 
μmol/L range have been sufficient for cell death. 52, 55 
 
Figure 5.7. Relationship between mg BACPT added to formation solution and (solid line) mg 
BACPT trapped in the particle batch and (dashed line) % of BACPT loading efficiency. The 
measurements shown are the average calculated values for the preparation types BACPT-HSAP-
1, BACPT-HSAP-4 and BACPT-HSAP-5. 
 
Figure 4.7 further illustrates the loading dynamics by showing that although the amount of 
drug increases with increased mg BACPT added to the formation solution (which might be 
expected), the percentage of drug loaded does not increase; decreasing from roughly 38-22% 
loading. This decrease confirms the idea of a loading plateau for 20 mg of HSAPs and may 
indicate some kind of binding competition or other kinetic influence. It was initially thought that 
as the amount of BACPT added to the formation solution decreased, the percentage of drug 
loaded should increase until all of the available drug was trapped inside, but the results dictated 
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that only a percentage of the available drug is binding to the HSA during BACPT-HSAP 
formation. 
 
Figure 5.8. Final BACPT-HSAP size compared to the amount of BACPT µg added to the 
preparation solution for individual samples. 
 
It is speculated that particle formation dynamics may play a role in loading.  More evidence 
that the particles size did not change in correlation to increasing amounts of BACPT present is 
shown in Figure 5.8; where the size consistency of BACPT-HSAPs is not effected by the drug 
mass trapped inside them, with all particles remaining within 211 to 270 nm diameter when 
loaded with 1.7 to 258 µg of BACPT. Taking that into consideration, one explanation for the 
percentage-based loading of the particles could be that some geographical section of the formed 
HSAP contains HSA which is available for drug binding and another portion of the HSAP 
contains HSA which is less capable of drug binding due to conformational changes responsible 
for the consistent sizing. That theory would have to be explored further to indicate a definitive 
answer.  
Some researchers have concluded that fluorescence should be used for quantitation of 
camptothecins, especially after exposure to HSA.109  Our own experience using HPLC for 
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BACPT analysis corroborated with this conclusion that intricate methodology is necessary for 
precise analysis.  
5.4.3 Determination of Loading Efficiency of BACPT via Fluorescence Spectroscopy 
In an effort to see how the structure of BACPT might be changing over time and to better 
quantitate loading efficiency, the sample supernatants and washes were analyzed by fluorescence 
spectroscopy and compared to a set of standards that were created at the same time.  In an effort 
to spare resources, we did not investigate this loading maximum, as it has been shown that 
BACPT concentrations in the μmol/L range have been sufficient for cell death. 52, 55 
Previous literature has shown that the fluorescence of BACPT does change over time, with 
conversion to the carboxylate form capable of happening in as little as 30 minutes in water.  
Since the particle solution we have used is 80% ethanol, the conversion was expected to happen 
more slowly, however it would still likely take place. A standard solution of 0.001 mg/mL 
BACPT in 50:50 water:ethanol was created and fluorescence spectroscopy was done with 
excitation at 403 nm with emission collected at 500 nm to monitor fluorescence changes. Twenty 
four hours later, the same standard solution was analyzed with fluorescence spectroscopy again.  
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Figure 5.9. Excitation and emission of 0.001 mg/mL solution of BACPT in 1:3 water:ethanol 
(solid lines) 30 minutes after creation and (dashed lines) 24 hours later. 
 
Figure 5.9 shows the excitation and emission spectrum of the BACPT standard within 30 
minutes after creation (solid lines) and 24 hours later (dashed lines). It is evident in the graph that 
there exists some decrease and shift in the fluorescence emission of the BACPT standard after 
only 24 hours in 50:50 water:ethanol. This would make it difficult to compare a sample 
supernatant to a standard of known concentration if the age of the solutions are different. In order 
to find out if the fluorescence change was concentration dependent, we prepared a set of 
standards of equal volume (all in 50:50 water:ethanol), but of varying concentrations of BACPT 
and measured the fluorescence intensity. Then, the standards were allowed to sit in the dark for 
24 hours and fluorescence intensity measurements were taken again. The fluorescence intensity 
of the standards measured within 30 minutes of creation and 24 hours later changed at the same 
rate.  
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Figure 5.10. Fluorescence Emission points for a series of 3 standard solutions (0.00001, 0.0001 
and 0.001 mg/mL) of BACPT in 1:3 water ethanol solvent (Solid trend line and diamond data 
point markers) within 30 minutes after creation and (Dashed lines) 24 hours later. 
 
Figure 5.10 represents calibration curves for the standards within 30 minutes (solid trend 
line) of creation and 24 hours later (dashed trend line). As seen in the graph, the standards 
change at the same rate, as shown by the linearity of the points. This means that the BACPT may 
in fact be changing to the carboxylate form (assuming this isn’t just representative of a loss of 
fluorescence in general), however the change is not dependent on drug concentration. Therefore, 
we can use fluorescence to analyze total BACPT present in the sample supernatant and washes, 
regardless of which form the BACPT is in, as long as the standards are created at the same time 
as the samples.  
Of course, sample analysis sooner rather than later post preparation is preferred.  However 
with the preparation process calling for at least 12 hours of formation and cross-linking time, 
there must be some lag in analysis time. The emission spectra for carboxylate and lactone forms 
of BACPT are so similar, that it can be difficult to tell them apart, as they both excite at 403 nm. 
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Figure 5.11. Relationship between mg BACPT added to formation solution and (solid line) µg 
BACPT trapped in the particle batch and (dashed line) % of BACPT loading efficiency. The 
measurements shown are the average calculated values for the preparation types BACPT-HSAP-
2, BACPT-HSAP-3 and BACPT-HSAP-4. 
 
Upon fluorescence analysis of BACPT-HSAPs prepared by either, BACPT-HSAP-2, 
BACPT-HSAP-3 or BACPT-HSAP-4, it can be seen in Figure 5.11 that there is a relationship 
between µg of BACPT added to the preparation solution and µg of BACPT that becomes 
encased in the HSAPs, just as in the case of HPLC analysis.  
Upon investigation of the percent of BACPT trapped versus the µg of BACPT added to the 
preparation solution, a discrepancy from HPLC becomes evident. When utilizing fluorescence 
for quantitation, the calculated average loading is reduced to 82 μg from 112 μg (as determined 
via HPLC) for a sample created with 500 μg  of BACPT added to initial preparation (method 
BACPT-HSAP-4) While 82 μg mg is inside of the calculated error for the BACPT-HSAP-4 
created batches, it is still worth considering that the HPLC method separated the carboxylate and 
lactone forms of BACPT differently in the standard solutions due to the water in the mobile 
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phase; possibly causing it to appear as though there was more BACPT present in the samples 
when compared to the peak areas of older standard solutions. 
Regardless of the quantitation method, there is evidence in both cases that BACPT is indeed 
becoming trapped within the HSAPs. The real test of whether or not the encapsulated BACPT is 
still effective at killing cancer cells was yet to be seen, therefore cell studies were done to 
determine that the combative properties of the BACPT had not been lost. 
This means that the BACPT may in fact be changing to the carboxylate form (assuming this 
isn’t just representative of a loss of fluorescence in general), however the change is not 
dependent on drug concentration. Therefore, fluorescence could be used to analyze total BACPT 
present in the sample supernatants and washes, regardless of which form the BACPT is in, as 
long as the standards are created at the same time as the samples. Of course, sample analysis 
sooner rather than later post preparation is preferred.  However with the preparation process 
calling for at least 12 hours of formation and cross-linking time, there must be some lag in 
analysis time. 
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Figure 5.12. Relationship between µg BACPT added to the sample formation solution and the 
average µg BACPT trapped in the BACPT-HSAPs. 
 
Upon analysis of BACPT-HSAPs prepared with either, 100, 250 or 500 µg BACPT, it can be 
seen in Figure 5.12 that 13 ± 7, 44 ± 10 and 82 ± 20 µg BACPT is entrapped, respectively. There 
is a linear relationship between µg of BACPT added to the preparation solution and µg of 
BACPT that becomes encased in the HSAPs. There is evidence that BACPT is indeed becoming 
trapped within the HSAPs. The real test of whether or not the encapsulated BACPT is still 
effective at killing cancer cells was yet to be seen, therefore cell studies were done to determine 
that the combative properties of the BACPT had not been lost.  
5.4.4 Human Sarcoma (CL) in vitro Cytotoxicity of Unloaded-HSAPs & BACPT-HSAPs  
Using untreated human sarcoma cancer cells (CL) as a cell control and Unloaded-HSAPs as a 
particle control, the BACPT-HSAPs were tested for visual cytotoxicity. In order to test the 
cytotoxicity of the unloaded-HSAPs, they were delivered at a concentration of ~9.1 X 1011 
HSAPs/ mL to the cells (theoretical particle creation calculation based on all 20 mg of HSA 
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forming 200 nm diameter spherical particles with density of 1.3 g/cm3). Figure 5.13a shows the 
CL cell control with no particles added, where cells are vital and continuing to grow and 
multiply. Figure 5.13b shows some inhibition of cell growth when unloaded HSAPs were added 
where most cells were inhibited to a rounded state without much multiplication, however some 
cells were still growing. With this high HSAP concentration, there is an increase in what seems 
to be aggregation of the particles around the cancer cells, causing the growth inhibition, however 
there doesn’t appear to be any cell death.  
This inhibition could be considered a positive result as it would confirm that the HSA 
particles are indeed attracted to and attaching themselves onto human cancer cells. This growth 
inhibition may not be an accurate reflection of what would happen in an in vivo scenario, when 
the HSAPs are not simply deposited on top of a few cells, but are allowed to distribute through a 
tumor site.   
 
 
 
Figure 5.13. Optical Image of Human Sarcoma Cells (CL) with A) no nanoparticles added. B) 
unloaded-HSAPs added 
a. b. 
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BACPT-HSAPs were tested for visual cytotoxicity as well using CELL METHOD 1. A 
BACPT-HSAP-4 preparation method yielded a particle batch with ~124 µg of BACPT trapped 
within 20 mg of HSAPs; the entire batch was dispersed into 4 mL of water and ultrasonicated. A 
BACPT-HSAP solution was diluted further in RPMI, yielding an effective BACPT drug dose 
delivered to the cell of approximately 15.5 ng. Decreased BACPT-HSAP amounts were initially 
chosen in order to not overwhelm the cells with particles, but to test the combative properties of 
the drug. Notably, in Figure 5.14, the lesser dose condition shows growth inhibition, cell 
blebbing and signs of apoptosis.  
 
Figure 5.14. Optical image of Human Sarcoma Cells (CL) with a diluted dose of BACPT-
HSANPs. Approximately 15.5 ng BACPT delivered. 
 
This low-dose anticancer activity was an extremely hopeful result. It is in-line with 
previous studies which have found that at low concentrations, J-type aggregates are formed by 
stacking of the BACPT rings, resulting in self- aggregation which prevents hydrolysis of the 
lactone ring at neutral pH, assuming they have come completely away from the HSA. 102   In one 
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study, BACPT showed the most potency when compared to six other classes of cancer drugs, 
including gemcitabine, the current gold standard for treatment of pancreatic cancer. BACPT was 
sixfold more potent than the gemcitabine and two to four logs more active than the other five 
drugs: vinorelbine, etoposide, dasatinib, 5-flurouracil and 5-azacytidine. 55  
5.4.5 Cytotoxicity of  BACPT-HSAPs of Varying Concentrations on Human Sarcoma 
(CL) 
Using CELL METHOD 2, BACPT-HSAPs were delivered to the CL cells without 
dilution, but with varying concentrations of drug loaded within; with overall higher drug 
dosages. Since the BACPT-HSAP solution aliquot delivered to the cells theoretically contains 
upwards of 100 billion particles, it could be hard to see the resulting vital state of the cells. It was 
decided that the cytotoxicity test would include incubating the cells which were stuck to the well 
plates with the particles, then removing the RPMI media, along with the particles and dead cells. 
 Three samples of BACPT-HSAPs were created via preparation methods BACPT-HSAP-
2, BACPT-HSAP-3 and BACPT-HSAP-4 with varying amounts of BACPT encapsulated within 
them (as determined via fluorescence): ~20, 37 and 74 µg, respectively. Without dilution, 0.1 mL 
of the BACPT-HSAPs were each delivered to separate CL cell samples in replicate, resulting in 
~2, 3.7 or 7.4 µg of encapsulated BACPT actually delivered to the cell well. No particles were 
added to the cell control.  
Figure 5.15 shows the cell plates after the particles and dead cells were removed. Figure 
5.15a shows that the untreated cells were able to thrive and continue to grow, even after washing. 
Cells treated with ~2, 3.7 and 7.4 µg (Figures 5.15b, 5.15c and 5.15d, respectively) show 
progressively less viable cells after treatment and washing; with Figure 5.15d having no cells 
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visible in the center of the well. This indicates that as the dosage of BACPT increased, more CL 
cells were killed, became unstuck from the plate, and were washed away.  
 
Figure 5.15. Optical image of Human Sarcoma Cells (CL) with (a) non-treated control cells and 
cells treated with a dose of BACPT-HSAPs containing (b) 2 µg, (c) 3.7 µg and (d) 7.4 µg of 
BACPT. 
 
It becomes obvious that these doses of BACPT are in fact effective for killing human 
sarcoma cancer cells in vitro. This proves that the amount of BACPT-HSAPs is not responsible 
for overwhelming the cells and killing them, but it is the concentration of the BACPT which is 
responsible for cell death. According to these findings that BACPT-HSAPs (likely with BACPT 
present in the carboxylate form) are effective at killing human sarcoma cancer cells.  
d. 
b. a. 
c. 
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Decidedly, in vivo work on an active animal model will give further insight into the 
effectiveness of BACPT-HSAPs under dynamic, realistic tumor conditions. Such in vivo 
experiments must be done to confirm cell growth and complete cytotoxicity. Also, the 
atmospherically oxygenated environment (20-21% oxygen) of the in vitro cell work presented 
here is not reflective of the hypoxic environment of a tumor site (1-2% oxygen), which causes 
the acidic extracellular environment. Since the cytotoxicity of most anticancer drugs is extremely 
pH dependent both in vitro and in vivo, a dynamic in vivo experiment is vital for further 
studies.58 
5.4.6 Formation and Characterization of CPT-HSANPs  
In an effort to compare the HSAP loading efficiency of the 7 and 10 carbon substituted 
BACPT with the parent drug camptothecin, CPT-HSAPs were prepared and analyzed. The CPT 
has a low solubility of < 1mg/ mL in ethanol. 110  Therefore, the camptothecin was dissolved in a 
mixture of 50:50 chloroform: ethanol.  Subsequent dilutions for the preparation of standards 
were done with 3:2 ethanol: water. Via dynamic light scattering, the CPT-HSAPs were found to 
have an average diameter of 475 ± 15 nm. These particles are larger than the BACPT-HSAPs, 
however they may have just been more susceptible to aggregation, due to the average zeta 
potential value being -12 ± 4 mV.  Either the CPT facilitates larger particle formation or it causes 
more attractive interactions between particles. 
5.4.7 Determination of Loading Efficiency of CPT 
 To determine the loading efficiency of CPT into the CPT-HSAPs, HPLC was chosen first 
again as a quantitative method of analysis.  Using a 40: 60 acetonitrile: water mobile phase, the 
CPT standards produced an analyte peak at 3.1 minutes. A standard solution of 0.01 mg CPT/ ml 
solvent (1:3 water: ethanol) was analyzed within 30 minutes of preparation and found to have a 
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peak area of 683 at 3.1 minutes. The same standards was analyzed 24 hours later on HPLC and 
found to have a significantly reduced peak area at 3.1 minutes.  Aside from the decrease at 3.1 
minutes, the aged standard showed new peaks at 0.9 minutes and 6.2 minutes. 
It was thought that peaks appearing at 0.9 to 1.2 min could be the open ringed, carboxylate 
version of the camptothecin molecules eluting from the column quickly in the mobile phase. The 
peak appearing at roughly 6.2 minutes was actually thought to be a lower concentration of the 
lactone version of the CPT. This is thought to be the portion of the lactone-CPT that is in water, 
thus lingering on the column longer; with only 40% acetonitrile not having the solvency strength 
to push it thought the column as quickly. Interestingly enough, the remaining peak at 3.1 
minutes, which is the time at which the CPT elutes in a freshly made CPT solution is thought to 
be the lactone-CPT stacking upon itself in the ethanol present in the solvent. 102  The stacking of 
the molecules cause an elution time slower than that of the carboxylate version being pulled off 
by the acetonitrile, but slower than the lactone version in water.  
When a solution of 0.001 mg of CPT in 1 mL of ethanol only was created and analyzed on 
HPLC, the analyte eluted at ~3.0 minutes with a peak area of 350 mA.U. Twenty four hours 
later, the standard solution eluted at the same time, but with a peak area of only 72 mA.U. There 
was not a large peak increase at 0.9 or 6.2 minutes to account for this elution loss at 3.0 minutes. 
Therefore, the molecule was likely sticking to the column, as the acetonitrile concentration was 
not strong enough to elute the CPT as it had when the sample was fresh.  
More experimentation would need to be done to confirm the sample breakdown hypothesis, 
proving information about the change in conformational states of the CPT over time.  However, 
for our purposes in this project, HPLC would not serve as an efficient method of analysis, as the 
solvent was playing too big of a role in the temporal integrity of the sample.     
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Again, fluorescence was chosen as the secondary means of quantitative analysis of the CPT 
washed off of the CPT-HSAPs.  Although, contrary to the case of BACPT, fluorescence 
measurements for CPT quantitation turned out to be even more elusive and sporadic. Samples of 
CPT-HSAPs were created for dosing the CL human sarcoma cell line, so the loading quantitation 
was attempted. The initial sample preparation solution for the treatment batch was made with 0.5 
mg of CPT, so batches of CPT-HSAPs were created with 0.1, 0.25 and 0.5 mg CPT in order to 
find a loading trend. 
Upon fluorescence spectroscopy, with excitation maximum at 358 nm and emission at  428 
nm, it was found that every batch of CPT-HSAPs created with carrying starting masses of CPT 
gave loading efficiencies of over 100%, despite have linear calibration curves for reference. This 
is not possible, so further fluorescence studies on standard solutions of CPT were performed.    
First, standards of 0.0005 mg CPT/ mL solvent were created in chloroform and ethanol only 
and in chloroform, ethanol and water (to more closely mimic the particle preparation matrix). 
The CPT solutions in chloroform and ethanol showed a decrease in fluorescence intensity over 
72 hours, as shown by Figure 5.16.  
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Figure 5.16.  Fluorescence excitation and emission spectra of 0.005 mg CPT/ mL in ethanol and 
chloroform, immediately after preparation and 72 hours later. 
 
Notably, when less than 1% water was present in the solvent matrix, the CPT fluorescence 
intensity remained the same for 72 hours (as did the excitation intensity), as seen in Figure 4.17. 
 
Figure 5.17. Fluorescence excitation and emission spectra of 0.005 mg CPT/ mL in ethanol, 
chloroform and 0.27% water, immediately after preparation and 72 hours later. 
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The reason the fluorescence intensity was not effected over 72 hours when water was present 
is not known. What is noticeable is that the solvent effects caused a difference in initial 
fluorescence intensity of roughly 598 for the chloroform:ethanol standard and roughly 558 for 
the standard containing as little as less than 1% water in the solvent matrix.  
Because the sample matrix never contains that little water (and initial supernatants and 
subsequent washes even contain varying amount of water), another solution of 0.0005 mg CPT/ 
mL solvent was created with 25 % water present along with the ethanol:chloroform matrix. As 
seen in Figure 5.18, this time, the fluorescence intensity of the solution did decrease over 24 
hours and continued to decrease as far as 9 days later. 
 
Figure 5.18. Fluorescence excitation and emission spectra of 0.005 mg CPT/ mL in ethanol, 
chloroform and 25% water, immediately after preparation, 24 hours later and 9 Days later. 
 
To see whether this decrease was concentration dependent, a set of standards of varying 
concentrations were made with the more realistic solvent matrix of 25% water and 75% 
ethanol:chloroform to study the fluorescence intensity change over 24 hours. Figure 5.19 shows 
the decline in CPT fluorescence intensity over 24 hours.  
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Figure 5.19. Fluorescence emission calibration curves for CPT standards with concentrations of 
0.00001, 0.0001 and 0.001 mg CPT/ mL in ethanol, chloroform and 25% water, immediately 
after preparation and 24 hours later. 
 
Although on first glance, the loss of fluorescence intensity does not seem to be concentration 
dependent, as noted by the linearity of the standards’ fluorescence change over time, Observing 
the actual fluorescence intensity values versus the concentration values (in Table 5.4) of the 
solutions gives another perspective:  
Table 5.4. Max fluorescence intensity for CPT solutions upon creation and 24 hours later. 
Concentration 
of CPT 
(mg/mL) 
MAX 
Fluorescence 
Intensity on 
DAY 1 
MAX 
Fluorescence 
Intensity on 
DAY 2 
0.00001 4.6 1.7
0.0001 11.2 11.1
0.001 330.7 109.3
 
At the lowest concentration of 0.00001 mg/mL, the CPT fluorescence intensity decreased by 
36%, but remained constant for the 0.0001 mg/mL CPT standard. Finally, the 0.001 mg/mL 
experienced a 33% decreased in fluorescence intensity. Either the 0.0001 mg/mL CPT solution 
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was an anomaly and kept its quantum efficiency or there was some error in the analysis. 
Regardless, the fluorescence intensity changes for the camptothecin are difficult to fully assess 
and would require more time and effort to comprehensively explain the kinetics of the opening 
of the lactone ring based on varying concentrations and solvent effects. 
Finally, the loss in fluorescence intensity is greater for CPT than BACPT over a twenty four 
hour period and is likely causing the sample supernatants to seem as though they contain more 
CPT than what was originally added to the preparation solution when compared to a decaying set 
of standards. It is a possibility that the HSA could be protecting the CPT from decaying s fast in 
the sample matrix in some way, but more studies would have to be performed to prove that 
theory. 
5.4.8 Cytotoxicity of  CPT-HSAPs of Varying Concentrations on Human Sarcoma (CL) 
Despite the trouble with completely and accurately quantifying the amount of CPT trapped 
within the CPT-HSAPs, the particles were still tested for cytotoxicity against the human sarcoma 
“CL” cell line.  A 20 µL aliquot of the final particle sample was added to a well containing the 
CL cells and termed a “high dose” of the particles. Figure 5.20 shows the cytotoxic effects of the 
particles. When compared to the human sarcoma CL control from Figure 5.13a and the HSAP 
control from Figure 5.13b, it is evident that these CPT-HSAPs cause cell death.  
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Figure 5.20. Optical Image of Human Sarcoma Cells (CL) treated with a “low dose” of CPT-
HSANPs. 
 
 When a 20 µL aliquot of 25% diluted CPT-HSAPs was added to the CL cells, the trial 
was termed a “low dose” particle delivery. Figure 5.21 shows the human sarcoma CL cells after 
incubation with a low dose of the CPT particles. Again, even when the particles were diluted, 
they still caused cell death.  Unfortunately, due to the quantitation issues surrounding the CPT, it 
is not known what the actual mass of drug present in the particle sample was. Without that 
knowledge and a valid method to continue quantitation, subsequent release studies could not be 
performed to try to determine what mass of camptothecin was responsible for causing this 
successful cytotoxicity result. 
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Figure 5.21. Optical image of Human Sarcoma Cells (CL) treated with a “low dose” of CPT-
HSANPs. 
5.5 Conclusions  
  This research has shown that the loading BACPT and CPT into HSAPs is possible with 
controlled particle size within 200-300 nm for the BACPT-HSAPs and 400-500 nm for the CPT-
HSAPs. The resulting BACPT-HSAPs are capable of encapsulation efficiency of at least up to 
21%. Moreover, the BACPT-HSAPs are visually cytotoxic to human sarcoma cancer cells down 
to a 15 ng dose, despite ideas that BACPT becomes irreversibly bound to HSA and subsequently 
medicinally inactive.  Further in vivo experiments need to be done to determine whether 
BACPT-HSAPs are an effective delivery mechanism for BACPT in an active tumor site and to 
determine whether there is a concentration of BACPT-HSAPs that is effective at delivering the 
drug in low enough concentrations that a patient’s organs and healthy cells are not at risk. 
 Unfortunately, the CPT loading quantitation could not be determined with either HPLC 
or fluorescence spectroscopy due to the water in the mobile phase during HPLC analysis and the 
erratic effects of the water in the sample preparation on the fluorescence emission of CPT. 
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Chapter 6 Summary and Conclusions 
 
In Chapter 2, composite AuNP-HSAPs, AuNS-HSAPs, and AuNR-HSAPs were successfully 
prepared as a proof of concept to show that these composite particles can serve as platforms for 
preparing new drug therapies. This research has shown that size-controlled encasement of these 
gold nanomaterials into larger (100-300 nm) HSAPs is possible via a desolvation and 
crosslinking process. This study served as the basis for the rest of the work. Proving gold 
nanomaterials could be encased in a bio-friendly protein shell which is large enough to load 
sufficient drug was important. Moreover, the same preparation parameter manipulations that 
allow for controllable particle size of medicinally useful HSAPs are in operation when the 
procedure is conducted with gold nanomaterials present. What we were left with was a template 
for future custom loading and surface functionalization.  
In Chapter 3, the first assessment of simultaneous loading of gold nanomaterials and proven 
chemotherapeutic drug proved successful with the formation of PAC-AuNR-HSAPs.  In addition 
to the loading capabilities, the photothermally active function of the gold was not lost after 
forming thiol bonds with the HSA or with any interaction with the drug. The combined approach 
will allow killing of cancer cells by both hyperthermia and localized chemotherapy treatment and 
is more likely to eliminate all cancer cells.  
 We saw that the level of heating could be controlled with the amount of gold present in the 
particles and the ‘doses’ of each preparation type. This is important because it allows for 
controlled heating, where a tumor in a particularly fragile site may not be able to receive 
complete ablation, however slight heating of the particles may result in an increase in drug 
uptake over time. The exact number of gold nanoparticles loaded into each HSAP to achieve 
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effective hyperthermic treatment safe enough for in vivo treatment is not yet known, but is the 
subject of ongoing studies, as is a step-wise increase in heating temperatures.   
In Chapter 4, hybrid AuNR-HSAPs were successfully prepared for in vitro studies and 
showed more controllable size distributions when more protein is added to the preparation vial. 
The particles were able to heat to necessary temperatures in order to cause renal cell carcinoma 
death, but careful consideration of the particle dose has to be maintained in order to not 
overwhelm the cells without irradiation.  Fluorescence uptake studies confirmed that the AuNR-
HSAPs are being taken up into the cancer cells, but are not entering the cell nuclei.  
Functionalizing the surface of the HSAPs with disease-specific targeting ligands may lead to 
even more effective delivery of cancer therapies to the site of the disease, boosting effectiveness 
and reducing damage to healthy tissue 42 
Finally, in Chapter 5, the research has shown that the loading BACPT and CPT into HSAPs 
is possible with controlled particle size and resulting BACPT-HSAPs are capable of 
encapsulation efficiency of at least up to 21%. Moreover, the BACPT-HSAPs are visually 
cytotoxic to human sarcoma cancer cells down to a 15 ng dose, despite ideas that BACPT 
becomes irreversibly bound to HSA and subsequently medicinally inactive.  CPT is also toxic to 
human sarcoma cells but the necessary loaded drug amount is not known. HPLC analysis proved 
unhelpful in assessing loading efficiency of the drugs due to the impeding mobile phase on the 
stability of the drug structure.   
Further in vivo experiments need to be done to determine whether BACPT-HSAPs are an 
effective delivery mechanism for BACPT in an active tumor site and to determine whether there 
is a concentration of BACPT-HSAPs that is effective at delivering the drug in low enough 
concentrations that a patient’s organs and healthy cells are not at risk.  
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Currently on-going studies include the loading of sorafenib (SRF), an angiogenesis inhibitor, 
into AuNR-HSAPs for use on renal cell carcinoma in vitro.  Animal studies are currently being 
arranged with our Tulane collaboration to assess the photothermal therapy capabilities of the 
AuNR-HSAPs as well as the hybrid effects of the sorafenib-loaded SRF-AuNR-HSAPs. Future 
studies will also include surface functionalization of targeting ligands to direct the hybrid 
particles to the tumor site as well as increase particle uptake. 
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